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Sub-Saharan Africa remains the region with the highest burden of HIV among both 
children and adults. Access to antiretroviral therapy (ART) has improved survival, yet data on 
long-term virological outcomes are scarce due to limited access to viral load monitoring. In 
addition, recent evidence indicates that HIV-infected ART-treated children are at increased risk 
of lung impairment compared to HIV-uninfected peers. The pathogenesis of lung complications 
in these children is currently unknown and data on the pathological mechanisms involved are 
limited. Due to the growing numbers of children with HIV surviving into adulthood, there is an 
urgent need for studies on the pathogenesis of lung impairment in this population group.  
Thus, the overall aim of this work was to study virological outcomes in individuals 
initiating ART in Harare, Zimbabwe and to investigate two components of host immune 
defence - nitric oxide (NO) and gut microbiota among HIV-infected ART-treated children and 
adolescents with and without lung impairment.   
In Paper I the rates of virological suppression as well as viraemia patterns were estimated 
in a retrospective cohort study of HIV-infected children and adults. We found that significantly 
more children than adults did not reach viral load suppression by 12 months ART. Among those 
who achieved viral suppression during the follow-up period, the incidence of viral failure was 
higher in children, as was the incidence of low level viraemia and viral blips.  
In Paper II, we found that HIV status was associated with lower exhaled NO levels. 
Notably, history of tuberculosis among HIV-infected children was associated with lower 
exhaled NO levels while airway obstruction alone was not. In addition, higher haemoglobin 
levels and neutrophil count were associated with higher exhaled NO levels in HIV-infected 
participants.  
Paper III demonstrated that HIV status was associated with lower gut species richness 
estimates. Prolonged ART treatment was significantly associated with a richer gut microbiota 
in HIV-infected children. At the same time, no association between airway obstruction or prior 
tuberculosis and gut biodiversity indices was observed in our study. HIV-infected participants 
were enriched in Corynebacterium, Finegoldia, Anaerococcus compared to HIV-uninfected 
participants.  
The present work stresses the importance of virological control in the paediatric HIV-
infected population. It explores the components potentially involved in the pathogenesis of lung 
impairment in these individuals. Low levels of exhaled NO may be a marker of HIV- and 
tuberculosis-induced alterations in pulmonary physiology while low gut biodiversity associated 
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1. HIV infection  
1.1. Current status of HIV epidemic 
In 2018, it was estimated that 37.9 million people were living with human 
immunodeficiency virus (HIV) worldwide, with 1.7 million of them younger than 15 years of 
age. More than half of HIV-infected adults and two-thirds of HIV-infected children reside in 
Sub-Saharan Africa (SSA) (1).  
Increased availability and uptake of antiretroviral therapy (ART) in the last two decades 
drastically improved survival and led to an increase in the number of people living with HIV 
worldwide. A large cohort study conducted in the USA reported an increase in life expectancy 
for HIV-infected persons at age 20 from 19.1 years in 1996-1997 to 53.1 years in 2011 (2). A 
large population-based cohort study in rural KwaZulu-Natal, South Africa, demonstrated an 
11.3 - year gain in adult life expectancy between 2003 (a year before ART became available in 
the public sector health system) and 2011 (3). However, despite improved survival, there is still 
at least an 11.8 year gap in life expectancy between HIV-infected and uninfected individuals 
(2).  
The annual number of new HIV infections worldwide has declined from 2.1 million in 
2010 to 1.7 million in 2018 (Figure 1). The greatest progress was made in Southern and Eastern 
Africa with 28% decline in the number of new HIV infections between 2010 and 2018 (1). The 
number of new HIV infections in children aged below 15 decreased from estimated 280 000 in 
2010 to 160 000 in 2018, probably due to widespread introduction of the programs for 
prevention of mother-to-child transmission (1).  
Globally, acquired immunodeficiency syndrome (AIDS)-related deaths decreased from 
its peak of 1.9 million in 2004 to 770 000 in 2018 (Figure 2) (1). Due to the scaling up of ART, 
AIDS-related mortality in Southern and Eastern Africa declined from 1 million in 2004 to 310 
000 and is now comparable to those reported in high-income settings (4, 5).  
In developed countries, the main causes of mortality in HIV-infected individuals have 
shifted from AIDS-defining to non-AIDS-defining conditions, that is chronic conditions similar 
to those in the general population. These now account for up to 84% of deaths in HIV infected 
individuals in the western countries (6-8). A similar trend is also observed in low- and middle-
income countries (9, 10). However, in these settings, AIDS-related conditions continue to be 
the major causes of death, with tuberculosis as the main cause accounting for up to 44% of 
deaths (10-12).  
 12 
 









1.2. A historical overview 
In 1981 a clinical syndrome characterized by profound immunodeficiency was reported 
in previously healthy young men who have sex with men in the USA (13). Patients were 
diagnosed with Pneumocystis pneumonia and Kaposi's sarcoma - conditions rarely observed in 
otherwise healthy individuals. This syndrome was called AIDS and was soon recognized in 
other groups such as injection drug users and patients with haemophilia (14, 15).   
HIV-1 virus - the causative agent for AIDS was isolated for the first time in 1983 from a 
lymph node biopsy of a patient with generalized lymphadenopathy by Luc Montagnier and 
Barre-Sinoussi at the Pasteur Institute in Paris (16). Three years later, in 1986, HIV-2 was 
isolated from two patients from Western Africa (17) at the same institute. Further studies 
provided evidence that both HIV-1 and HIV-2 are the result of cross-species transmission of 
simian immunodeficiency virus (18).  
The rapid spread of AIDS around the world was accompanied by extensive research of 
the newly discovered virus and potential treatment options. Already in 1987 zidovudine, a drug 
which inhibits the HIV enzyme reverse transcriptase, was found to decrease mortality and 
frequency of opportunistic infections in patients with AIDS (19). However, rapid development 
of viral resistance to zidovudine forced the scientific community to search for new approaches 
to treat HIV.   
One of the main milestones in HIV research was achieved a decade later (in 1996) with 
the introduction of highly active ART - a combination of at least three antiretroviral drugs in 
order to limit the development of resistance. Introduction of combined ART resulted in a 
dramatic decline in HIV morbidity and mortality and an increase in life expectancy (3, 20, 21). 
Due to high treatment costs these achievements were primarily seen in developed 
countries. However, the Drug Access Initiative launched in 1997 by The Joint United Nations 
program on HIV and AIDS (UNAIDS) drastically improved ART coverage in resource-limited 
settings (RLS). The first patients received drugs in Uganda and Cote d'Ivoire soon after in 1998. 
 
1.3. HIV virus, pathogenesis, natural history and treatment 
HIV-1 and HIV-2 belong to the Lentiviridae subfamily of retroviruses. Though both 
viruses cause AIDS, HIV-1 is more aggressive and is responsible for the global HIV pandemic. 
HIV-2 infection dominates in West African countries, is less virulent, and has lower rates of 
transmission and a slower progression to AIDS (22).  The modes of transmission for HIV-2 are 
the same as for HIV-1.  
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The virus is transmitted by sexual intercourse, parenteral inoculation (intravenous 
injection) and from mother to child. Mother-to-child transmission (MTCT) of HIV occurs in 
utero, during delivery and postnatally through breastfeeding. Late postnatal transmission by 
breastfeeding represents a considerable further risk, accounting for up to 42% of overall MTCT 
of HIV (23). 
HIV infects CD4 T lymphocytes (CD4 cells), monocytes, macrophages and dendritic 
cells via binding to CD4 membrane receptors and chemokine coreceptors (C-C chemokine 
receptor type 5 or C-X-C chemokine receptor type 4) (24). Cells such as astrocytes and renal 
epithelial cells may also be infected leading to HIV-associated neurocognitive disorders and 
nephropathy (25, 26). Once the virus enters the cell, HIV RNA and HIV enzymes are released 
(Figure 3). Reverse transcriptase converts viral HIV RNA into HIV DNA. Viral DNA then 
migrates into the cell’s nucleus and integrates into the host’s DNA. This step is mediated by 
viral integrase. New HIV RNA and HIV proteins are then generated by utilizing the cell’s own 
transcription mechanisms and move further to the cell surface and form immature 
(noninfectious) HIV particles. Once the virus is released from the cell, HIV protease mediates 
the formation of the mature infectious virus.  
The early phase of HIV infection is characterized by high levels of viral replication and 
massive depletion of CD4 cells, which are the primary targets of the virus (27-29). Depletion 
and functional impairment of these cells are crucial points in disease progression. As the result 
of rapid virus replication, individuals become viraemic shortly after infection. Already this 
stage of the disease is accompanied by an intense pro-inflammatory response characterized by 
elevation of a broad range of cytokines and chemokines in the systemic circulation ("intense 
early cytokine storm") (30). Antibodies against HIV are detectable within 4-6 weeks after 
contracting HIV. This period is called seroconversion and individuals may develop flu-like 
symptoms during this period (31, 32). After seroconversion, the plasma viral load (VL) 
decreases and reaches the steady state level (the so-called "VL set point"). The initial acute 
decrease in CD4 cells is followed by CD4 cell recovery to almost normal levels which without 
treatment gradually decline with time. Patients may remain asymptomatic for years until CD4 
cell levels fall below 200 cells/mm3 and the individual becomes susceptible to a wide variety 
of opportunistic infections (such as Mycobacterium tuberculosis, Pneumocystis pneumonia, 
cryptococcal meningitis, candidiasis, etc.) and HIV-related malignancies (Kaposi's sarcoma, 




Figure 3. HIV life cycle. Source: National Institute of Allergy and Infectious Diseases. 
www.niaid.nih.gov/diseases-conditions/hiv-replication-cycle. 
 
A very small proportion of individuals (less than 0.5% of those infected) called long-term 
nonprogressors may maintain low level viraemia and stable CD4 counts (³500 copies/ml) for 
more than 10 years without treatment (34). A subgroup of these individuals called "elite 
controllers" have no detectable viraemia (35, 36).  
 
ART and current approach to treatment 
The HPTN 052 clinical trial, named as the 2011 Breakthrough of the Year by the Journal 
of Science, demonstrated a 96% reduction of sexual transmission of HIV with early initiation 
of ART compared with delayed treatment (37). This study became fundamental for our current 
view on treatment and follow-up of HIV-infected individuals and paved the way for further 
research. The proposed mechanism of the effect of ART was sustained VL suppression in 
genital secretions. The findings were later confirmed by a plethora of studies, also in the 
homosexual population (38-43). A study by Rodger et al. conducted among 1166 serodifferent 
heterosexual and men who have sex with men (MSM) couples where the HIV-infected partners 
received ART showed they had undetectable VL and reported condomless sex found no 
documented cases of within couple HIV transmission during 1.3 years of follow-up (44).  
Supported by these and other studies, the World Health Organization (WHO) updated 
guidelines in 2016, where ART treatment has been recommended to all HIV-infected 
individuals regardless of WHO clinical stage and CD4 count (45). In addition, these 
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recommendations highlight HIV VL measurement as the preferred approach to monitor 
treatment response and detect treatment failure. CD4 count testing (which guided ART 
initiation and treatment response for more than two decades) is no longer recommended for 
monitoring of patients who are stable on ART in settings were VL measurement is routinely 
available (46). However, due to financial constraints (high costs for VL testing) clinicians in 
RLS still rely on CD4 count monitoring with limited access to routine VL testing.  
Currently, treatment of HIV is initiated with an ART regimen consisting of two 
nucleoside reverse transcriptase inhibitors (NRTIs) plus either a non-nucleoside reverse 
transcriptase inhibitor (NNRTI), protease inhibitor (PI) or integrase inhibitor (24, 47). Due to 
similar suppression rates and tolerability of these combinations, clinicians in high-income 
countries can choose the most appropriate regimen for a patient by taking into account potential 
adverse effects, ease of administration, drug interactions and costs (48). In case of treatment 
failure, HIV drug resistance testing is performed with a subsequent switch in ART regimen. 
For RLS with limited access to drug resistance testing, the WHO recommends a public 
health approach with 2 NRTI + NNRTI as a standardized first-line ART for children >3 years 
and adults and subsequent switch to a second-line ART with 2 NRTI + PI in case of treatment 
failure. PI-based regimens are recommended for infants and children younger than 3 years  (47).  
Routine VL monitoring is recommended at 6 and 12 months after ART initiation and then 
every 12 months in order to monitor treatment response and to detect treatment failure. 
Detectable VL (thresholds vary) in individuals on ART should prompt enhanced adherence 
counselling and a repeat VL test within 6 weeks. Adherence counselling is an essential 
component of ART treatment with data showing that up to 70% of HIV-infected individuals 
with detectable VL are re-suppressed after adherence counselling (49, 50). Two sequential VL 
measurements above certain threshold imply viral failure (VF) and require HIV drug resistance 
testing and ART regimen changes (47).  
 
2. Challenges of HIV in the era of ART 
2.1. Lack of universal definitions for virological outcomes  
The goal of ART is to achieve sustained VL suppression in order to prevent HIV 
progression, development of HIV drug resistance mutations and to minimize the risk of HIV 
transmission.  However, thresholds for VL suppression and VF are a matter of debate. Many 
countries in SSA use WHO cut-offs with VF defined as two sequential VL measurements 
³1000 copies/ml (47). WHO guidelines justify the 1000 copies/ml threshold for VF based on 
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the data showing low risk of HIV transmission with VL below 1000 copies/ml (47, 51, 52). 
Another important reason why the WHO recommends this cut-off is that many RLS use dried 
blood spots for VL measurement which have a substantially higher VL detection threshold 
compared to plasma samples (550-1000 copies/ml vs 20 copies/ml, respectively), but provide 
an opportunity for easy transport and storage compared to plasma (53).   
However, a number of studies conducted in developed countries demonstrate that patients 
with VL below 1000 copies/ml are still at increased risk of VF compared to patients with 
undetectable VL or VL suppression at <50 copies/ml, with some studies advocating for even 
lower cut-offs (54-56). Therefore, guidelines for high-income settings define VL suppression 
as VL below the lower limit of detection of commercial assays, which is usually below 50 
copies/ml and VF as VL above 200 copies/ml in two or more consecutive VL measurements 
(57, 58).  
HIV-infected individuals may also experience episodes of transient detectable viraemia 
after initial VL suppression despite being on ART. The spectrum of these episodes includes 
viral blips, low level viraemia (LLV) and viral rebound. As with VL suppression and VF cut-
offs, the definitions used for these viraemia episodesvary across different studies and guidelines 
(57-59). For example, blips are defined as transiently detectable VL<400 copies/ml in the 
Department of Health and Human Services guidelines (60), 50-200 copies/ml in Spanish 
guidelines (61), single VL 50-400 copies/ml preceded and followed by undetectable VL in 
British guidelines (57) and transient VL 50-1000 copies/ml in WHO guidelines (47).  
Different definitions used for VL suppression, VF and detectable viraemia episodes 
across different settings often complicate the comparison between published data. In addition, 
due to lack of national VL monitoring programs in many RLS, the majority of data available 
on VL suppression in SSA comes from cross-sectional studies and clinical trials with a paucity 
of data from longitudinal cohorts. A recent systematic review and meta-analysis comprising 
data on 125 distinct populations in SSA found that the proportion of viral suppression was 
significantly lower in cohort studies compared to trials at 12 months ART and tended to be 
lower also at 24 months (62). This highlights the fact that clinical trials tend to overestimate 
VL suppression and may not reflect the “real-world” situation.  
 
2.2. Virological outcomes in individuals on ART  
The majority of studies conducted in high-income countries report high rates of VL 
suppression among adults ranging from 80.9% to up to 95.3% (63-65). Similar suppression 
rates were reported among perinatally infected children in the UK and Ireland with 92% of 
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children achieving VL suppression within 12 months since ART initiation (66). An 
international multicentre trial (PENPACT-1) conducted among HIV-infected children in 
Europe, North and South America demonstrated that 84% reach VL<400 copies/ml after the 
median follow-up of 5 years on ART (67). 
Due to scaling up of ART in SSA, the proportion of HIV-infected individuals who receive 
ART treatment in this area has dramatically increased during the last decade. As a result the 
reported VL suppression rates among the adult HIV-infected population in SSA are now 
comparable to high-income settings and range from 85.4% to 92.6% (68-71).  
However, the results are less encouraging when it comes to VL suppression rates in the 
paediatric HIV-infected population in RLS. A large meta-analysis of data from 72 studies found 
that the proportion of children aged <18 years in low- and middle-income countries who 
achieved VL suppression after 12 months ART ranged from 64.7% to 74.7% during the first 
two decades of the 21st century (72, 73). This is considerably lower than VL suppression rates 
previously reported in adults from the same settings and in children from high-income settings 
(66, 74).  
A number of studies conducted both in high- and low-income settings highlight that 
children and adolescents are less likely to achieve VL suppression and are more prone to VF 
compared to adults (75-77). Murphy et al. reported that only half (51.4%) of children and 
adolescents who achieved initial VL suppression maintained undetectable VL for a year (76). 
The reported rates of VF among children and adolescents in SSA are high, with up to 64% of 
ART-treated children and adolescents experiencing VF (64% in Senegal; 51.6% in Togo; 
30.6% in Zimbabwe) (78-80). A study conducted in Cameroon among HIV-infected 
adolescents who were on ART for a median of 7 years found that 20.7% of adolescents were in 
VF (³1000 copies/ml) (81). It is important to note that, due to lack of resources, regular VL 
testing is not routinely implemented in many sub-Saharan countries. Therefore, data available 
on VL levels are often obtained from cross-sectional studies and lack information on initial VL 
suppression as well as confirmative (second) VL testing in the case of detectable viraemia (79, 
80). However, a recent cohort study among children aged<12 years who initiated ART in South 
Africa found that 20.1% of those who reached initial VL suppression had subsequent VL 
rebound (defined as at least one VL >1000 copies/m after initial VL suppression) (82).  
A number of factors may contribute to worse virological outcomes in HIV-infected 
children and adolescents compared to adults. Lack of paediatric ART formulations, poor 
tolerability and palatability, and presence of comorbid conditions (low nutritional status, 
advanced HIV stage) complicate treatment of children with HIV (83). However, lack of 
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adherence is the biggest challenge in treatment of HIV-infected paediatric population (84, 85). 
It can be caused by any of the abovementioned factors as well as psychosocial issues and lack 
of knowledge about why the treatment is needed (83). Adolescence is a period for particularly 
high risk for poor adherence (86, 87) with data showing that individuals above 15 years of age 
have a higher risk of non-adherence compared to younger individuals (88). In addition, 
retention in care is substantially lower among children and adolescents compared to adults with 
data showing that up to 38% are lost to follow-up after 24 months ART (89, 90).  
All these data highlight that a number of challenges exist in treatment, monitoring and 
retention in care of HIV-infected children and adolescents. Specific models of medical care 
oriented towards young individuals growing up with HIV should be developed in order to 
improve treatment outcomes and retention in care.   
 
2.3. Episodes of detectable viraemia 
Episodes of detectable viraemia (viral blips, LLV, residual viraemia) after initial VL 
suppression are common among individuals on ART. Detectable viraemia episodes do not 
necessarily indicate treatment failure, but may contribute to persistent inflammation and 
immune activation leading to further HIV progression (91, 92). 
Such factors as high baseline (pre-treatment) VL, shorter duration of ART since treatment 
initiation, specific ART combinations and the presence of transmitted drug resistance mutations 
have been shown to be independent predictors of detectable viraemia (93-97).   
There is also evidence that detectable viraemia may facilitate the selection of drug-
resistant HIV variants. This is especially important in SSA, where suppression rates are lower 
than in developed countries, and diagnostic and treatment options are limited (73). Swenson et 
al. found that patients with detected drug-resistant mutations during LLV episodes are three 
times more likely to experience VF in future (98).  
HIV viraemia accompanied by chronic inflammation may further contribute to the 
development of chronic HIV-associated complications which are now increasingly recognized 
in individuals on ART (99-102). 
 
2.4. Chronic comorbidities in HIV-infected individuals  
Due to the introduction of ART, people with HIV live longer and are at risk of developing 
chronic comorbidities related to ageing. However, recent evidence indicates that chronic 
comorbidities are more common among HIV-infected individuals compared to the HIV-
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uninfected population and that factors other than accelerated ageing may be the main triggers 
in the development of these complications (7, 103, 104).  HIV viraemia, CD4 cell lymphopenia, 
co-infections, and translocation of microbial products from gastrointestinal (GI) tract may all 
lead to persistent inflammation and accelerate the development of these complications (99-102, 
105).  
Among the most commonly observed chronic disorders in HIV-infected adults are 
cardiovascular disorders (hypertension, myocardial infarction) (106), pulmonary disorders 
(103, 107), diabetes (108) and non-AIDS defining malignancies (109). 
ART has transformed HIV infection into a chronic, manageable disease, with treatment 
focus shifting towards assessing chronic conditions. With improved access to ART, those 
complications are more and more common among HIV-infected individuals in RLS.  
 
3. Lung complications associated with HIV infection  
3.1. Infectious complications  
Ongoing HIV replication accompanied by chronic inflammation impairs the immune 
response against infectious stimuli thus increasing susceptibility to respiratory infections. This 
results in the high frequency of respiratory infections observed in HIV-infected individuals, 
with lung tuberculosis (TB), Pneumocystis pneumonia and community-acquired pneumonia 
being the most commonly observed (110, 111). Although the frequency of these HIV-
associated complications has considerably decreased in the ART era, they are still common in 
HIV-infected individuals. In developed countries bacterial pneumonia (with Streptococcus 
pneumoniae as the causative agent) is the most frequently diagnosed lung infection among 
people with HIV, while TB remains the major health threat in developing settings (112, 113). 
 
Tuberculosis in HIV-infected individuals 
Among the estimated 10 million people who developed TB in 2017, 9% (920 000) of the 
incident TB cases occurred in people with HIV (113, 114). Although the global incidence of 
active TB is falling, it remains the leading cause of death in HIV-infected individuals in low- 
and middle-income countries.  
HIV increases the risk of developing active TB in individuals with latent Mycobacterium 
tuberculosis (Mtb) infection and in those who are newly exposed to TB (115, 116). Moreover, 
HIV-infected children and adults are at higher risk of rapid disease progression and TB 
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recurrence (117-119). A study conducted in Ethiopia found that HIV-infected children were six 
times more likely to die during the episode of TB compared to HIV-uninfected children (120).  
ART is an effective preventive tool against TB in HIV-infected individuals (121). One of 
the most impressive effects of ART was shown in Brazil by Miranda et al., with 80% reduction 
in incident TB in ART-treated HIV-infected individuals compared to ART-naïve (122). Despite 
this dramatic effect of ART, TB incidence rates in individuals on long-term ART are still higher 
than in general population (116, 123, 124).  
Advanced immunosuppression at treatment initiation (low CD4 count and high VL) and 
poor nutritional status are associated with increased risk of TB in HIV-infected individuals who 
receive ART (123, 125, 126). This is especially important for perinatally HIV-infected children 
who, due to suboptimal early infant diagnosis of HIV, are often diagnosed late in older 
childhood and adolescence when they have already developed advanced immunosuppression. 
Moreover, it was recently shown that ongoing HIV replication is an independent risk factor for 
TB in ART-treated HIV-infected individuals regardless of CD4 count (127). This emphasizes 
the need to maintain (long-term) suppressed VL and to prioritize routine VL monitoring in 
individuals on ART. 
Given the high risk of progression to active TB, WHO guidelines recommend preventive 
treatment of TB for adults and adolescents living with HIV who are unlikely to have active TB 
and have a positive or unknown tuberculin skin test. Treatment with isoniazid should be 
initiated irrespective of the degree of immunosuppression, history of prior TB and pregnancy 
(128).  
 
3.2. Burden of chronic lung diseases in HIV-infected individuals 
The ART era is characterized by the growing burden of chronic lung complications 
among HIV-infected individuals, with chronic obstructive pulmonary disease (COPD) being 
most frequently reported (110, 129-131).  
COPD is characterized by reduced lung function assessed by spirometry. In a large 
prospective study among treated HIV-infected adults in Denmark, HIV was independently 
associated with 197 ml lower forced expiratory volume in one second (FEV1) and 328 ml lower 
forced vital capacity (FVC) (132). HIV is currently acknowledged as a risk factor for COPD 
development in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 
for diagnosis, management and prevention of COPD (133).  
According to a recent meta-analysis, the estimated global prevalence of COPD in HIV-
infected individuals is 10.5% (134). While the majority of the reports on chronic lung diseases 
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comes from high-income settings, these complications are now more and more often recognized 
among HIV-infected individuals in developing settings (135).  
Recent data indicate that HIV-infected paediatric populations often present with chronic 
respiratory symptoms and airway abnormalities (136, 137). The most common patterns of HIV-
associated lung impairment in children include lower airway obstruction and reduced diffusion 
capacity  (138). In a study where lung function was assessed by a broad range of tests it was 
shown that HIV-infected children and adolescents have lower FEV1, FVC, FEV1/FVC, 
diffusing capacity of carbon monoxide, respiratory system compliance and functional residual 
capacity and higher airway resistance and lung clearance index compared to age- and ethnicity-
matched HIV-uninfected controls (139). Moreover, there is some evidence that HIV-infected 
children are less likely to have reversibility after bronchodilator probing compared to HIV-
exposed uninfected children suggesting that maternal HIV infection may affect fetal lung 
development (136, 140).  
Presence of chronic lung complications may in turn worsen clinical status in individuals 
with HIV and compromise long-term outcomes. A nationwide population-based COPD 
diagnoses study found that HIV-infected individuals had higher incidence rates of hospital 
admissions for COPD and higher in-hospital mortality compared to HIV-uninfected individuals 
with COPD (141).  Another study found that HIV-infected individuals with airway obstruction 
(FEV1/FVC <0.7) had a 3-fold higher risk of death compared to those without airway 
obstruction (142).  
 
3.3. Pathogenesis of lung impairment in HIV  
Progression of COPD is characterized by accumulation of inflammatory mucous exudate 
in the lumen of the small airways and infiltration of the airway wall by inflammatory immune 
cells (143). This is accompanied by airway wall thickening with subsequent lung function 
decline and development of airway obstruction (144).  
Risk behaviours such as cigarette smoking and injection drug use are known risk factors 
for COPD, and contribute to the development of the disease probably to the same degree as in 
the general population (103, 137, 145). However, data indicate the presence of 
pathophysiological factors unique to HIV infection. 
  
HIV in the lung 
HIV impairs host defence mechanisms in the lung and persists in alveolar macrophages 
(AM) and lung CD4 cells even in ART-treated individuals with undetectable plasma VL (146, 
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147). Ongoing HIV replication in AM leads to progressive depletion of lung CD4 cells and 
dysregulation of lung immunity (148). In addition, HIV increases H2O2 levels in the alveolar 
space and the expression of oxidative stress markers in AM (149). This in turn stimulates 
oxidant-mediated lung injury and lung fibrosis.   
 
Systemic inflammation and residual HIV viraemia 
Besides the direct effects of the virus on the lung, systemic inflammation and ongoing 
HIV viraemia may also contribute to lung damage. For example, increased levels of systemic 
inflammatory biomarkers such as C-reactive protein, interleukin-6, T-cell activation markers 
(CD25, CD69), endothelin-1, D-dimer, and serum amyloid A were associated with lower lung 
function parameters in individuals with HIV infection (150-152). Another study found that high 
plasma VL is associated with increased risk of spirometry-defined obstructive lung disease in 
HIV-infected individuals (153). This is especially important for perinatally-infected children 
due to challenges related to long-term virological control, life-long treatment, and longer life 
expectancy. 
 
Role of respiratory tract infections 
High susceptibility to respiratory tract infections in HIV-infected individuals also 
contributes to the development of chronic lung complications. Impaired immune response to 
infectious agents may increase the risk of microbial colonization of the respiratory tract or 
decrease the ability to clear sub-clinical infections (154). Colonization by the microorganisms 
in turn induces a pro-inflammatory response with increased levels of cytokines, chemokines 
and proteases. The inability to eliminate pathogens results in tissue re-modelling, airway 
thickening and lung function decline.  
 
Role of prior TB   
History of prior TB infection may also contribute to lung impairment in HIV-infected 
individuals.  
Despite successful treatment, TB leads to incomplete immune restoration. Mtb may 
escape immune mechanisms and persist in AM in a non-replicating state, without symptoms in 
the host for prolonged periods of time (155, 156). Non-replicating persistence of Mtb maintains 
chronic airway inflammation and facilitates lung impairment (157).  
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3.4. Role of prior TB in lung impairment in HIV-infected individuals 
The ongoing TB epidemic in developing settings and high number of HIV-infected 
individuals with active TB in anamnesis contribute to the high prevalence of chronic lung 
disorders in this population. TB-induced scarring results in the loss of parenchymal tissues, 
which explains restrictive abnormalities observed on spirometry in patients with active TB in 
anamnesis (158). In addition, a number of studies report that individuals with a history of prior 
TB are also at increased risk of airway obstruction (158-160). A meta-analysis of eleven studies 
found a strong association (pooled odds ratio 3.05) between a history of TB and the presence 
of COPD (161). The mechanisms responsible for obstruction are less clear but may be explained 
by the development of bronchiectasis and bronchial stenosis as the result of lung tissue 
remodelling.  
Interestingly, in a study conducted among individuals in Tanzania who completed at least 
20 weeks of anti-TB treatment, the prevalence of an obstructive spirometry pattern was 
significantly higher than restrictive (42% vs 13%) and airway obstruction was more common 
in HIV-infected compared to HIV-uninfected participants (66.7% vs 52.4%) (162). This finding 
indicates that both TB and HIV may interact and synergistically promote the development of 
airway obstruction. 
Moreover, TB may exacerbate symptoms in individuals with an already established 
diagnosis of COPD. Jin et al. showed that COPD patients with TB in anamnesis have more 
severe dyspnoea, a higher prevalence of bronchiectasis and higher percentage of severe 
bronchiectasis compared to COPD patients without previous TB (163).  
Data on post-TB lung impairment in HIV-infected individuals in SSA are scarce. One 
recent study conducted in Cameroon showed that 45.4% of patients with a history of treated 
TB have lung function impairment, with restrictive pattern being the most common (164).  
Given the high burden of HIV-TB co-infection, it may be difficult to separate the effects 
of HIV from TB sequelae on lung status. A recent study conducted in South Africa found that 
the association between HIV status and airway obstruction is mediated by history of TB or 
pneumonia (135). This may imply the potential underestimation of the role of prior TB in the 
progression of lung impairment in HIV-infected individuals, especially in high TB-burden 
settings. 
 
3.5. Methods to assess airway abnormalities 
As previously mentioned, the main pattern of lung impairment observed in HIV-infected 
individuals is chronic airway obstruction that can be detected via lung function tests. A number 
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of techniques such as spirometry, plethysmography, impulse oscillometry, and exhaled nitric 
oxide are used to assess lung status.     
 
3.5.1. Spirometry 
The most widely used method to assess lung function is spirometry, which measures the 
volume and flow of the inhaled and exhaled air. It is used for diagnosis, severity grading and 
monitoring of COPD and asthma patients. Spirometry is the most reproducible and objective 
measure of airflow limitation and is the gold standard for measurement of lung function 
according to GOLD guidelines (133). Two of the most widely utilized spirometry parameters 
are FEV1 (reflects the volume of air that the individual is able to exhale during the first second 
of forced expiration) and FVC (reflects the total volume of air that the individual is able to 
forcibly exhale in one breath). An abnormally low ratio of FEV1 and FVC is used to diagnose 
airflow limitation while FEV1 is used to grade the severity of airway obstruction (165). Since 
the estimated parameters are age-, height-, sex- and ethnicity-dependent, the estimates obtained 
from the individual are compared to established reference values. Reference values are 
estimated from reference equations that contain data from large population surveys.  
Standardized criteria and the availability of portable devices makes spirometry the most 
popular screening tool in individuals with chronic respiratory symptoms and suspected airway 
abnormalities. The majority of reports on lung abnormalities in HIV-infected individuals 
utilized spirometry for lung function assessment (135, 139, 166, 167).  
 
3.5.2. Exhaled nitric oxide   
Besides lung volumes, a number of techniques exist to measure certain molecules in 
exhaled air (exhaled breath analysis). These include measurement of nitric oxide (NO), carbon 
monoxide, volatile organic compounds and biomarkers in exhaled breath condensate. The most 
extensively studied signalling molecule in exhaled air is NO.   
 
Discovery of nitric oxide 
In 1980 Furchgott RF and Zawadzki JV reported that endothelial cells produced a 
substance that relaxed vascular smooth muscles (168). At that time the molecule was called 
endothelium-derived relaxing factor. Later, it was concluded that endothelium-derived relaxing 
factor is a gaseous NO molecule. Since its discovery, the role of NO in various physiological 
and pathological studies has been widely investigated (169, 170). In 1991 NO was detected for 
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the first time in the exhaled air in humans and two years later, increased levels of exhaled NO 
(eNO) were reported in asthmatic patients (171, 172). Due to the discovery of NO as an 
important signalling molecule in physiology, immunology, cardiology and neuroscience it was 
named molecule of the year by the Journal of Science in 1992. At present, NO is the most 
extensively studied exhaled airway biomarker.  
 
Nitric oxide and its role in the lung 
NO is generated by the conversion of the amino acid L-arginine to L-citrulline and NO 
by the enzyme called NO synthase (NOS). At present three isoforms of NOS are known: 
neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS). Two isoforms, 
nNOS and eNOS, are expressed constitutively and are activated by calcium ions to produce 
NO. This NO plays role in a number of physiological processes such as vasodilation, blood 
pressure control, inhibition of the haemostatic system and neuronal signalling (173, 174). In the 
airways NO regulates bronchodilation and vascular basal tone, counteracts hypoxic 
vasoconstriction and stimulates airway submucosal gland secretion (175). iNOS is not normally 
expressed, but induced by endogenous (chemokines, cytokines) and exogenous (bacterial 
toxins, viral infection, allergens, environmental pollutants) factors, leading to the production of 
large amounts of NO independently of calcium ion influx. There is some evidence that iNOS-
derived NO has a role in regulation of airway smooth muscle tone and inflammatory response 
(175). 
Mixing of alveolar NO with NO in the conducting airways during exhalation results in 
the observed expiratory NO concentration, which can be detected in the exhaled air with special 
instruments.  
 
Measurement of nitric oxide in exhaled air 
A number of techniques are currently available for eNO measurement, including 
chemiluminescence, electrochemical detection, laser-based technology and extractive 
electrospray ionization mass spectrometry (176, 177). Though chemiluminescence is the gold 
standard for NO measurement, portable electrochemical systems for eNO measurements are 
currently widely used. These machines contain an electrochemical sensor which converts gas 
concentration into electrical signals. The machine's sensor produces a signal which is directly 




Clinical utility of exhaled nitric oxide testing 
The clinical utility of eNO testing has been most widely studied in asthma. Increased eNO 
levels in asthmatic patients are thought to be the result of iNOS overexpression due to 
eosinophilic airway inflammation. Evidence suggests that eNO may be a useful tool to guide 
asthma management in both children and adults (178, 179).  
Reduced eNO levels are reported in patients with cystic fibrosis (180-182) and active TB 
(183, 184), though its role in disease management is still unclear. Among mechanisms which 
may explain reduced eNO levels are lack of the substrate (L-arginine), reduced activity of iNOS 
in the airways, increased NO catabolism or thick mucus which inhibits the NO diffusion into 
exhaled air (e.g. in cystic fibrosis) (185-187).  
The data regarding the eNO levels in other lung disorders such as bronchiolitis obliterans, 
bronchiectasis, interstitial lung disease, and COPD are contradictory (188-190). However, one 
recently published study demonstrated that eNO can predict clinical response to inhaled 
corticosteroids in adults with nonspecific respiratory symptoms (191). 
 
 
4. HIV infection and gut microbiota  
4.1. Gut microbiota in health and disease 
In recent years there has been increased interest in researching the role of gut microbiota 
both in health and disease. Gut microbiota refers to the trillions of microorganisms which 
colonize the GI tract. In healthy individuals, over 90% of gut bacterial species are represented 
by three phyla: Bacteroidetes, Firmicutes and Proteobacteria (192). A balance of commensal 
microorganisms is needed in order to maintain the integrity of the gut mucosal barrier, the host-
microbiota homeostasis and defence against pathogenic organisms (193).  
Alteration in the composition of the gut microbiome (gut dysbiosis) has been linked to 
the pathogenesis of various disorders such as inflammatory bowel syndrome, atopy, type 2 
diabetes, obesity, rheumatoid arthritis, multiple sclerosis, and cardiovascular disorders (194-
200). Gut dysbiosis is characterized by significantly decreased microbial diversity and a shift 
towards pathogenic species (201). Moreover, recent evidence indicates that gut microbiota is 
involved in the maintaining of lung health, with altered gut microbiome composition observed 
in lung diseases such as asthma and cystic fibrosis (202-204). Low gut microbiome diversity 
during infancy has been linked to asthma development during school age (205).   
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4.2. Alterations in gut microbiota associated with HIV infection 
The early phase of HIV infection is characterized by massive depletion of CD4 cells, 
primarily in the intestinal mucosa (29). Studies show that CD4 cells in the GI tract are depleted 
disproportionately compared to CD4 cells in peripheral blood and lymphoid tissues (27). 
Massive depletion of mucosal CD4 cells causes structural impairment of the gut epithelial 
barrier, leading to translocation of microbes and microbial products into systemic circulation 
(microbial translocation) and alterations in the gut microbiota (206, 207).   
Alpha diversity of the gut microbiota is decreased in HIV-infected adults compared to 
healthy controls (208-210). These findings were reported in both ART-naïve and ART-treated 
individuals, emphasizing that treatment cannot fully restore the gut microbial composition. In 
addition, HIV-associated dysbiosis is characterized by decreased abundance of commensal 
(protective) bacteria and an enrichment in potentially pathogenic taxa such as Pseudomonas, 
Enterobacteriaceae, Acinetobacter and Campylobacter (211-214).  
Data also suggest that HIV-induced alterations in gut microbiota are accompanied by 
immune activation and chronic inflammation (206, 209, 214, 215). For example, a number of 
studies demonstrated that alpha diversity of the gut microbiota correlates positively with CD4 
cell count, and negatively with microbial translocation markers such as plasma 
lipopolysaccharide and  lipopolysaccharide binding protein (208, 216). In addition, associations 
between specific taxa and markers of microbial translocation and systemic inflammation in 
HIV-infected individuals were reported in a number of studies (217, 218). Dinh et al. found a 
significant positive correlation between relative abundance of Enterobacteriaceae and 
interleukin-1b and interferon-γ in patients who received ART and had undetectable plasma VL 
(218). Increased relative abundance of Prevotella in HIV-infected individuals was associated 
with increased mucosal and systemic T cell activation markers (217). In addition to the 
microbiota’s effect on persistent inflammation, there is some evidence that enrichment in 
certain species may impact treatment outcomes in individuals initiating ART. For example, Lee 
et al. showed that a relative abundance of Fusobacterium negatively correlated with CD4 count 
and was independently associated with poorer CD4 cell recovery following ART initiation 
(219). In addition, a number of studies tried to link gut dysbiosis to the development of chronic 
complications in HIV-infected individuals, but findings are inconsistent (220-224).  
Notably, all these studies were conducted in HIV-infected adults with a paucity of data 
on gut microbiota in perinatally HIV-infected individuals. So far, only one recent study 
examined fecal microbiota in 29 HIV-infected children, 14 of whom were treatment naïve and 
15 who received ART (225). In this study, decreased alpha diversity and increased relative 
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abundance of Prevotella was observed in HIV-infected children regardless of ART status. 
Notably, in ART-treated children, relative abundance of Prevotella positively correlated with 
plasma soluble CD14 levels, a marker of microbial translocation and all-cause mortality. These 
findings emphasize that certain microorganisms that colonize the GI tract may drive chronic 
inflammation in HIV-infected ART-treated individuals and may potentially contribute to the 
development of chronic complications.  
To the best of our knowledge, no studies on gut microbiota have been conducted in HIV-
infected individuals with lung complications. However, recent evidence indicates that the gut 
microbiome is involved in the maintaining of lung health, and altered gut microbiome 
composition is often observed in lung diseases in HIV-uninfected populations (202, 203). Low 
gut microbiome diversity during infancy has been linked to asthma development during school 
age (205). Antosca et al. found distinct stool microbiota in infants with cystic fibrosis compared 
to healthy controls and showed a link between gut microbiota and airway exacerbations in 
infants with cystic fibrosis (226). Given the severe gut dysbiosis observed in HIV, one can 










Aims of the thesis 
The overall aim of this thesis was to investigate the role of HIV viraemia and factors that may 




Specific objectives were: 
1. Study the rates of viral suppression among children and adults initiating ART and 
factors associated with initial viral non-suppression (Paper I). 
2. Study the incidence, patterns and risk factors of detectable viraemia in individuals who 
achieved initial viral suppression (Paper I). 
3. Investigate the levels of eNO in HIV-infected children and adolescents and study the 
association between airway abnormalities (history of prior TB, airway obstruction) in HIV-
infected individuals and eNO levels (Paper II). 
4. Study the composition of gut microbiota in HIV-infected children and adolescents and 







Materials and methods 
1. Study setting and study design 
The present study was conducted in Harare, Zimbabwe. The country is located in southern 
Africa with a population of approximately 16 million people (Figure 4). In 2018 there were an 
estimated 1.3 million HIV-infected people in the country of whom 84 000 were children aged 
below 15 (1). Unprotected heterosexual sex is the most common HIV transmission route among 
adults, while MTCT is predominant in children. 
ART was introduced into the public health care system in 2004 and is currently provided 
free of charge by government clinics as well as by a number of non-governmental (not-for-
profit) organizations. An estimated 88% of HIV-infected individuals had access to ART in 2018 
(1) .  
 
 
Figure 4. Map of Zimbabwe 
 
For Paper I retrospective analysis of data collected at Newlands Clinic (Harare, 
Zimbabwe) was performed. Newlands Clinic is a not-for-profit HIV clinic established in 2004 
by the Swiss not-for-profit organization Ruedi Lüthy Foundation. The clinic provides 
comprehensive HIV care to over 6000 HIV-infected patients within urban and peri-urban 
Harare and Chitungwiza. ART as well as routine six-monthly VL monitoring are provided free 
of charge. Newlands Clinic also offers psychosocial and nutritional support, special services 
for children and occupational skills training for adolescents and young adults (227).  
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For Paper II and Paper III, a cross-sectional study was conducted in Harare Children’s 
Hospital - a public sector clinic which provides care for more than 4000 HIV-infected children 
and adolescents.  
 
2. Study population 
For Paper I the study population was comprised of HIV-infected individuals of all ages 
who initiated ART at Newlands Clinic during the period August 2013-August 2015 and who 
had at least two VL tests after treatment initiation. Participants were followed until September 
2017. 
For papers II and Paper III individuals found eligible for the BREATHE (Broncho-
pulmonary function in response to azithromycin treatment for chronic lung disease in HIV-
infected children and adolescents) trial were approached. BREATHE is a randomized 
controlled trial (RCT) among HIV-infected children and adolescents with chronic lung disease 
(CLD) attending two hospitals in Harare, Zimbabwe and Blantyre, Malawi (clinicaltrials.gov 
identifier NCT 02426112). The main objective of the trial is to investigate whether long-term 
treatment with azithromycin results in improvement of lung function in HIV-infected children 
with CLD.  
For the purpose of the present work only participants enrolled in Harare, Zimbabwe were 
approached. Participants were eligible for the trial if they were aged 6-19, on ART for at least 
6 months, had no evidence of active TB or acute respiratory tract infection and had fixed airway 
obstruction defined as FEV1 z-score less than -1 with no reversibility (<12% improvement in 
FEV1 after salbutamol 200 ug inhaled using a spacer). A comparison group of HIV-infected 
participants with normal lung function, no active TB or acute respiratory tract infection at the 
time of enrolment, no history of chronic respiratory symptoms in the last 3 months and MRC 
dyspnoea score <2 was enrolled specifically for the laboratory sub-studies. The detailed 
BREATHE study protocol has been published elsewhere (228).  
In addition, a group of HIV-uninfected participants was recruited from the same 
catchment area as the HIV-infected group. HIV-uninfected participants aged 6-16 years with 
no active TB or other respiratory or heart disorders in anamnesis, no reported chest pain after 
exercise, no shortness of breath during exercise, no chronic cough and normal lung function 
were enrolled.  
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HIV-infected participants recruited during the period April 2017-August 2018 and June 
2016-January 2018 were included in Paper II and Paper III, respectively. All HIV-uninfected 
participants for the present work were recruited during the period April - July 2017. 
 
3. Data collection and study procedures 
Paper I 
For Paper I we obtained anonymized data from medical records on HIV-infected 
individuals who were in care at Newlands Clinic during the period August 2013-September 
2017.  
The following variables were extracted from medical records: age, sex, date of ART 
initiation, ART regimen, adherence, height, weight, clinical history (WHO HIV disease stage, 
history of TB, opportunistic infections, chronic comorbidities), and laboratory parameters (VL, 
CD4 count, haemoglobin) at the time of ART initiation and during the follow-up period. 
 
Paper II-III 
For Papers II and III, questionnaires were used; clinical examination, eNO testing and 
spirometry were performed; and blood samples and rectal swabs were collected.  
 
Questionnaires 
All study participants completed a detailed, standardized questionnaire regarding 
demographic characteristics, details on HIV diagnosis and treatment, clinical history and 
presence of respiratory symptoms (chronic cough, wheezing, dyspnoea) at the time of 
examination and in the past 3 months. Self-reported and physician-diagnosed heart, lung 
(including history of prior TB and asthma) and other disorders were recorded.  
For Paper II, an additional questionnaire regarding asthma, eczema (atopic dermatitis), 
allergic rhinitis, allergic conjunctivitis, food allergy symptoms and diagnosis, the use of 
medications and exposure to tobacco smoke was administered. Full versions of the 
questionnaires are presented in Appendices I, II, III (BREATHE forms: B0.03a, B0.03b, 
B0.15).   
Clinical examination included measurement of weight, height, respiratory rate, heart rate 
and oxygen saturation measured by pulse oximetry (OxyWatch, Beiijing Choice Electronic 
Technology Co. Ltd) 
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Exhaled NO measurement 
Exhaled NO was measured using the portable electrochemical system NIOX VERO 
(Circassia, UK). The machine contains an electrochemical sensor which converts gas 
concentration into electrical signals. The machine's sensor produces a signal which is directly 
proportional to the partial NO pressure and thus to NO concentration in the studied sample 
(176). The machine has a measurement range between 5 parts per billion (ppb) and 300 ppb.  
eNO measurements were performed according to American Thoracic Society (ATS) 
guidelines (229). The calibration of the device and quality control were performed according 
to the manufacturer’s instructions. All eNO measurements were performed between 08:00 and 
14:00 h prior to spirometry, and the exact time of testing was recorded. The participants were 
asked to sit and rest for a minimum of 5 minutes before testing. Repeated exhalations with a 
minimum of 30 seconds rest time in between were performed in order to obtain at least two 
measurements that agreed within 10%. Up to six measurement attempts were made and the 
mean eNO value was calculated from two eNO measurements with minimal differences 
between them.  
 
Spirometry 
Spirometry was performed using the EasyOne portable spirometer (ndd Medical 
Technologies Inc., Andover, MA, USA). Spirometry was performed according to the ATS 
guidelines (230). Up to eight forced exhalations were recorded. The largest FEV1 and FVC for 
each individual were recorded. FEV1 and FVC were expressed as z-scores using Global Lung 
Function Initiative reference ranges (231). The z-score shows how many standard deviations 
(SD) the measured value is away from the mean predicted value (for example, a value of 0 is 
the expected value and the value  -1 is one SD below the mean) (165). Participants with FEV1 
z-score <-1 repeated spirometry 15 minutes after administration of 200µcg inhaled salbutamol 
via spacer. The largest values for post-FEV1 and post-FVC were recorded. 
 
Blood tests   
Blood samples were collected for full blood count tests, and for participants with HIV, 
also for HIV VL and CD4 count testing. HIV VL was measured using the Gene Xpert assay 
(XpertTM HIV-1 Viral Load; Cepheid, Sunnyvale, CA, USA), with a lower limit of detection 
of 40 copies/ml and CD4 count was measured as a point of care test using a PimaTM Analyser 
(Alere, Orlando, FL, USA). 
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Collection of rectal swabs 
Study nurses collected rectal swabs from all participants at study enrolment. Samples 
were obtained by inserting the swab approximately 2-3 cm inside the rectum, ensuring that 
swabs were visibly stained with faeces. Swabs were immediately preserved in 1.5 ml of 
transport medium PrimeStore ® MTM (Longhorn diagnostics, Maryland, USA) and directly 
stored on ice for a maximum of one hour before being frozen at -80 °C. Frozen samples were 
shipped on dry ice to the laboratory at Division of Medical Microbiology, University of Cape 
Town, South Africa. Upon arrival, the samples were stored at -80°C until further processing.  
 
Processing of rectal swabs at the University of Cape Town  
DNA extraction 
The Zymo Research Quick-DNATM Fecal/Soil Microbe Microprep kit (Zymo Research, 
California, USA) was used for DNA extractions. DNA was extracted according to the 
manufacturer’s protocol.  
 
16S library preparation and gene sequencing 
In order to assess DNA quality and the total bacterial load extracted, a real-time 
quantitative polymerase chain reaction (PCR) was performed as previously described (232). 
Subsequently, two sets of PCRs targeting the V4 hypervariable region of the 16S ribosomal 
ribonucleic acid (rRNA) gene using the primers 515F and 806R were performed according to 
previously described protocols (233, 234).  
Amplicons were cleaned using the Agencourt® AMPure® XP PCR Purification kit 
(Beckman Coulter, California, USA) as previously described (234). Each of the purified PCR 
products was quantified using the QuantiFluor® dsDNA System quantification kit on Promega 
Glomax®-Multi Detection system (Promega, Wisconsin, USA) (234). Product sizes were 
confirmed using agarose gel electrophoresis (234). PCR products were pooled to a normalized 
concentration of 120 ng. Gel excision and purification were performed on the final pool using 
a 1.6% agarose gel (234). The purified library size was determined using the Agilent 2100 
bioanalyzer using hsDNA kit, and quantified using the KAPA PCR quantification kit (KAPA 
Biosystems, Massachusetts, USA) (234). 
Samples were sequenced on an Illumina Miseq® instrument using the Miseq® Reagent 
v3 kit, (600 cycles) (Illumina, California, USA). The final library was diluted to a 6 pM 
concentration, and a 25% PhiX library spike-in was added at 6 pM as internal control (235). 
The pre-processing of sequence reads was done using the H3ABioNet 16S rDNA diversity 
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analysis package (https://github.com/h3abionet/h3abionet16S), with the exception that the 
taxonomy of representative reads was assigned using the SILVA version 132 database. The raw 
sequence files have been submitted to the European Nucleotide Archive under the accession 
number PRJEB32077.  
Sequencing controls, including the ZymoBIOMICS microbial community standards, and 
biological samples were analysed separately. The average sequence reads of each operational 
taxonomic unit detected in the spiked controls (except from the DNA these controls were spiked 
with) were calculated and subtracted from the biological samples. In the biological replicates 
the number of reads between the two replicates varied (+/- 20%), but the taxonomic profiles 
were completely overlapping. In addition, the replicated samples separated into four clusters 
both after alpha and beta diversity analysis, confirming technical reproducibility of the run. 
 
Data Storage (Paper II, Paper III) 
Electronic clinical record forms (Google Nexus tablets, Google, Mountain View, CA, 
USA) with OpenDataKit software (opendatakit.org) and paper forms were used for data 
collection. Data from paper forms were extracted using CARDIFF TELEFORM character 
optical mark recognition software (Version 10.9, Vista, CA, USA). Data were transferred to 
Microsoft Access database (Microsoft, Redmond, WA, USA) and then exported for analysis.  
 
4. Definitions 
Adherence to ART - number of tablets dispensed at the last visit minus the number of 
tablets returned at current visit divided by number of tablets that should have been consumed 
between visits.  
Airway obstruction was defined as FEV1 z-score <-1.64 with no reversibility.  
Alpha diversity refers to the richness of bacterial taxa and relative abundances of the 
different species within a single sample.  
Anaemia was defined according to WHO criteria (haemoglobin <11 g/dl for children <5 
years; <11.5 g/dl for children 5-11.9 years; <12 g/dl for children 12-14.9 years; <12 g/dl for 
females aged ³15 years; <13 g/dl for males aged ³15 years) (236).  
Asthma was defined based on clinical history of diagnosed asthma or self-reported 
symptoms of asthma or treatment with asthma-specific medications.  
Atopic disorders were defined based on self-reported episodes of allergic rhinitis, 
conjunctivitis and eczema (atopic dermatitis) and/or physician diagnosed atopic disorder.  
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Beta diversity refers to interindividual differences within groups and was determined 
using Bray-Curtis dissimilarity index (237) with sample depth set at 2000 reads.  
Low level viraemia - at least two consecutive viral load measurements 50-1000 
copies/ml followed by viral load <50 copies/ml.  
Stunting was defined as height-for-age z-score less than -2 for participants aged £19. 
WHO reference standards or British 1990 Growth Reference Curves were used to calculate z-
scores (238, 239). 
Underweight (wasting) was defined as weight-for-age z-score or body mass index 
(BMI)-for-age z-score less than -2 for participants aged £19 or BMI<18.5 kg/m2 for participants 
aged >19. WHO reference standards or British 1990 Growth Reference Curves were used to 
calculate z-scores (238, 239).  
Viral blip – a single episode of viral load ³50 copies/ml preceded and followed by viral 
load<50 copies/ml.  
Viral failure – viral load ³1000 copies/ml in two consecutive viral load measurements 
after initial VL suppression.  
Viral load non-suppression – failure to achieve viral load suppression by 12 months on 
ART.  
Viral load refers to the number of HIV RNA copies per millilitre of blood. 
Viral load suppression – two consecutive viral load measurements <50 copies/ml after 
ART initiation. 
 
5. Statistical analyses  
Continuous variables were reported as mean and standard deviation (SD) or median and 
interquartile range (IQR). Continuous parameters between study groups were compared using 
t-test (in case of normal distribution) and Wilcoxon rank sum or Kruskal-Wallis test (in case of 
skewed distribution); categorical parameters were compared using chi-squared test or Fisher’s 
exact test. All statistical tests were two-tailed and p-value < 0.05 was considered statistically 
significant. 
 
Paper I   
The proportion of participants who did not achieve VL suppression by 12 months ART 
(the 12 months cut-off was chosen to allow for a VL test to confirm suppression at month 12) 
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was estimated and the factors associated with VL non-suppression were studied using logistic 
regression.  
The incidence rates of viral blips, LLV and VF were estimated, and Nelson-Aalen 
cumulative hazard curves were plotted for those who had at least two VL tests after initial VL 
suppression. We used survival analysis to study the factors associated with occurrence of viral 
blips. For the model, participants were included into analysis at time 0 (time of first suppressed 
VL test after ART initiation) and followed until a viral blip occurred or until the last VL test 
available. Participants who reported treatment interruption in ART for more than two weeks 
were excluded from this analysis. Since the estimated cumulative hazard of blips increased 
exponentially with time, we fitted the parametric survival regression with Weibull distribution 
stratified by age groups. The value of P (the shape parameter) >1 confirmed that the hazard of 
failure (viral blip) increased with time.  
The following variables were studied as predictors of VL non-suppression and viral blips: 
age, sex, BMI, stunting (in children only), history of TB before ART initiation, chronic 
comorbidities (adults only), WHO clinical stage at ART initiation (1-2 vs 3-4), ART regimen 
at treatment initiation (NNRTI-based vs PI-based),  adherence, CD4 count, pre-treatment VL, 
anaemia. Age, sex and CD4 count at ART initiation were adjusted for a priori. All analyses 




The values of eNO were not normally distributed and therefore presented as geometric 
mean with 95% confidence interval (CI). The analyses were performed with log-transformed 
eNO data and back transformed to present geometric mean.  
The association between eNO levels and explanatory variables was studied using linear 
regression analysis. Explanatory variables included HIV status, age, sex, anthropometric 
parameters, haemoglobin level, haematocrit, white blood cell count, neutrophil count, 
eosinophil count, FEV1 z-score, atopic status, and passive smoking for all participants. The 
additional variables CD4 count, VL, history of TB and presence of airway obstruction were 
included for participants with HIV only. Age, sex and exact time of eNO testing were adjusted 
for a priori.  
Parameters were included into the multivariable linear regression model if they showed 
a significant effect on the prediction of eNO level in age-, sex- and time of eNO testing adjusted 
models at p<0.05. Adjustment for unbalanced parameters (for HIV-infected group) was also 
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performed. Variance inflation factor was used to detect multicollinearity in the multivariable 
models. The linear association between eNO and continuous variables was estimated 
graphically. Residual analysis with residual plots and normal probability plots of residuals 
confirmed no violation of the linear regression assumptions. 
 
Paper III  
The following alpha diversity estimates were calculated - the number of operational 
taxonomic units (OTUs), Chao1 index (240) and Shannon index (241). Alpha diversity indices 
between study groups were compared using Wilcoxon rank-sum test and p-values were 
corrected for multiple testing using false discovery rate (FDR) procedure. Spearman´s rank 
correlation with Bonferroni correction was used to assess the association between alpha 
diversity indices and continuous parameters. We fitted the linear regression model in order to 
estimate the association between HIV status and alpha diversity indices. BMI, age, sex were 
adjusted for a priori. An interaction term between HIV status and antibiotics in the three 
previous months (co-trimoxazole prophylaxis for HIV-infected group) was included into the 
regression model to determine whether antibiotics modify the effect of HIV status on alpha 
diversity estimates. The association between other participant characteristics and alpha 
diversity indices was further evaluated in regression analysis stratified by HIV status. The 
following participant characteristics were studied: stunted, underweight, FEV1 z-score, 
episodes of diarrhoea for all participants; VL, CD4 count, years on ART, co-trimoxazole 
prophylaxis, diagnosis of CLD, ART regimen, history of prior TB - for HIV-infected 
participants. Age and sex were adjusted for a priori.  
Beta diversity comparisons were performed using Principal Coordinate plots. 
Comparisons were made using the Wilcoxon rank sum test. Kruskal-Wallis test was used in 
cases where more than two groups were compared and the same groups were compared using 
the permutational multivariate analysis of variance (242), with number of permutations set to 
999. P-values were adjusted for multiple testing using the Benjamini-Hochberg method (243). 
 
Relative abundance 
Relative abundance was assessed in a linear discriminant analysis using linear 
discriminant analysis effect size (LEfSe) (244) with default settings (alpha values for the 
statistical test 0.05). To reduce the number of markers, the effect size threshold was set to 1.0 
for the plots. Heatmaps were generated using only the taxa that were significantly different 
using the LEfSe comparison. The average fraction of each taxa was calculated from all samples 
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within each group. The data were transformed to fractional abundance before performing the 
LEfSe analysis. All p-values reported were corrected for multiple testing using FDR.  
Statistical analyses were performed in STATA 14 (StataCorp LLC, College Station, 
Texas, USA).   In addition, for Paper III, analyses of beta diversity were performed using stats 
package in R Statistical software (http://www.r-project.org/) and QIIME2 (version 2018.4); 
relative abundance comparisons plots were generated using the MicrobiomeAnalyst web-based 
software tool with standard feature filtering (245). 
 
6. Ethical approval 
Paper I 
Ethical approval was obtained from the Newlands Clinic Research Committee, the 
Medical Research Council of Zimbabwe, and Regional Committee for Medical and Health 
Research Ethics (Norway).  
 
Paper II, III 
The study was approved by the London School of Hygiene and Tropical Medicine Ethics 
Committee; the Harare Central Hospital Ethics Committee; the Medical Research Council of 
Zimbabwe; Regional Committee for Medical and Health Research Ethics in Norway. Written 
informed consent by guardian and assent by participants aged <18 years were sought. Consent 







1. Paper I 
In Paper I, the rates and risk factors for detectable viraemia were investigated in a cohort 
of HIV-infected children and adults who initiated ART at Newlands Clinic (Harare, 
Zimbabwe). Among 725 participants who initiated ART between 2013 and 2015, 127 children 
(0-19 years) and 503 adults (>19 years) were included in the analysis. The median (IQR) 
follow-up time was 2.8 (2.3-3.2) and 2.7 (1.8-2.8) years for children and adults, respectively.  
Of the 630 participants, significantly more children than adults did not achieve VL 
suppression by 12 months following ART initiation (19.7% children vs 5.6% adults, p<0.001). 
In adults, younger age and CD4 count £200 cells/mm3 at ART initiation were significantly 
associated with not achieving VL suppression in logistic regression analysis. 
During the follow-up period, 106 (83.5%) children and 482 (95.8%) adults reached VL 
suppression. The median (IQR) time to VL suppression was 0.5 (0.4-1.3) and 0.5 (0.2-0.8) years 
in children and adults, respectively. 
Among those who reached VL suppression, 516 participants had sufficient VL data to 
study the incidence of detectable viraemia episodes. In total, 57 (11%) participants experienced 
a viral blip. Blips occurred more commonly in children than in adults (22.9% vs 8.3%, 
p<0.001), with the incidence rate being 10.9 (95% CI 7.2-16.6) and 4.0 (95% CI 2.8-5.5) per 
100 person years in children and adults, respectively. In survival analysis no baseline 
characteristics were found to be significantly associated with increased risk of viral blips in 
children or adults. 
Seven (1.4%) participants (4 children and 3 adults) experienced LLV and 12 (2.3%) 
participants (8 children and 4 adults) developed VF after initial VL suppression during follow-
up. The incidence of LLV was higher in children (1.9 (95% CI 0.7-5.1) vs 0.3 (95% CI 0.1-1.0) 
per 100 person years, p=0.03), as was the incidence of VF (4.0 (95% CI 2.0-7.9) vs 0.4 (95% 
CI 0.2-1.2) per 100 person years, p<0.001). All four adults with VF re-suppressed while only 
three children re-suppressed during the follow-up period. 
 
2. Paper II 
In this paper we compared the levels of eNO in children with and without HIV and 
investigated the association between eNO and history of TB and airway obstruction in HIV-
infected children on ART. In total, 222 HIV-infected and 97 HIV-uninfected participants were 
included in analysis. Among HIV-infected participants 57 (25.7%) had a history of TB in 
anamnesis and 56 (25.2%) had airway obstruction but no TB in anamnesis. Overall, HIV-
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infected children were more likely to be wasted, stunted and to have anaemia compared to HIV-
uninfected participants (wasted: 41.9% vs 3.1%, p<0.001; stunted: 42.8% vs 4.1%, p<0.001; 
anaemia: 31.2% vs 9.3%, p<0.001). HIV status was associated with lower eNO levels after 
adjusting for age, sex and time of eNO testing (geometric mean ratio 0.79 (95% CI 0.65-0.97), 
p=0.03).  
Among HIV-infected participants, those with a history of TB had significantly lower eNO 
levels compared to those without TB whether they had airway obstruction (geometric mean 
13.7 (95% CI 12.2-15.5) vs 16.9 (95% CI 14.3-19.8), p=0.03) or had no airway abnormalities 
(geometric mean 17.9 (95% CI 16.0-20.0), p=0.003). History of TB remained significantly 
associated with lower eNO levels in linear regression analysis after adjustment for age, sex and 
time of eNO testing. In multivariable analysis history of TB, haemoglobin, neutrophil count, 
and age were significantly associated with eNO levels in this study group.  
Among HIV-uninfected participants, only wasting, haemoglobin and age were 
significantly associated with eNO levels in multivariable analysis.  
 
3. Paper III 
In Paper III we investigated the composition of gut microbiota in HIV-infected and HIV-
uninfected children and studied the association between participant characteristics and gut 
microbiota. In total, 149 HIV-infected participants with diagnosis of CLD, 28 HIV-infected 
participants without diagnosis of CLD, and 103 HIV-uninfected controls were included into the 
study.  
HIV status was associated with lower species richness estimates (OTUs, Chao1 index) in 
linear regression analysis adjusted for BMI, age and sex (b coefficient (95% CI); OTUs: -18.8 
(-35.0 to -2.6) p=0.02; Chao1: -34.7 (-55.7 to -13.7), p=0.001). The association remained 
borderline significant for OTUs and significant for Chao1 index once antibiotic use in the 
previous 3 months were introduced into the regression model (OTUs: -26.5 (-54.8 to 1.89), 
p=0.07; Chao1 index: -42.3 (-79.1 to -5.6), p=0.02). No association between HIV status and 
Shannon index was observed.  
HIV-infected participants with suppressed VL had borderline higher OTUs (Median 
(IQR): 192.5 (145.5-228.5) vs 176 (138-220), p=0.06) and higher Chao1 index (259.3 (201.2-
302.1) vs 233.2 (175-276), p=0.02) compared to participants with VF. The negative association 
between VF and Chao1 index remained borderline significant in regression analysis adjusted 
for age and sex (-19.4 (-40.5 to 1.73), p=0.07)). 
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Once HIV-infected participants were split into groups based on ART treatment duration 
(<5 y; 5-10 y; ³10 y), we found that participants who had been on ART ³10 years had alpha 
diversity estimates that were similar to the HIV-uninfected participants. Among participant 
characteristics, prolonged ART treatment was the only parameter significantly associated with 
a richer gut microbiota in HIV-infected children after adjustment for age and sex. No 
association between diagnosis of CLD and alpha diversity indices was observed in the study.  
 
Beta diversity 
Beta diversity was significantly higher among HIV-infected participants compared to 
HIV-uninfected group (p<0.01).  
 
Relative abundance of specific taxa 
At phylum level HIV-infected participants had significantly lower abundance of 
Epsilonbacteraeota (7% vs 13%, p<0.01) and Bacteroidetes (32% vs 38%, p<0.01) compared 
to HIV-uninfected controls. At genus level HIV-infected participants were enriched in 
Corynebacterium (p<0.01), Finegoldia (p<0.01), Anaerococcus (p<0.01) compared to HIV-
uninfected participants.  
HIV-infected participants with CLD had a higher abundance of Faecalibacterium 
(p=0.05) compared to those without CLD. Enrichment of Enterobacteriaceae (p=0.02) and 
Burkholderiaceae (p=0.04) was observed in HIV-infected children with CD4 counts £400 
cells/mm3. Notably, the longer the participants had been on ART, the fewer taxa were found to 








1. Discussion of the main results   
1.1. Virological outcomes in individuals initiating ART  
In Paper I we found that 83.5% of children and 95.8% of adults reached VL suppression 
after ART initiation. The rates of VL suppression are close to those reported in high-income 
settings and indicate that Zimbabwe is on its way to achieve the third UNAIDS target of 90% 
of those on ART have VL suppressed.  
Other studies performed in SSA and other RLS report widely varying VF rates, ranging 
from 4% to 52% depending on study design, population and setting (79, 246-249). In contrast, 
only a small proportion of HIV-infected individuals developed VF during follow-up in our 
study. This may be explained by several reasons.   
First, VL monitoring is not implemented as a routine test in many RLS and the majority 
of data on VF come primarily from cross-sectional studies with no information about initial VL 
suppression or a confirmative VL test in case of detectable viraemia. Moreover, the VF 
threshold may also vary depending on the guidelines implemented.  
If one defines VF based on a single measurement, the results do not discriminate between 
“true” VF, and transient viraemia. An example of the so-called "VL snapshot" is a study 
conducted in Togo which demonstrated strikingly high rates of VF among children and 
adolescents with 52% having VL>1000 copies/ml in a single VL test (79). In contrast to this 
report, the longitudinal design of our study allowed us to distinguish those who did not reach 
VL suppression since ART initiation from those who experienced detectable viraemia (either 
single episodes of raised VL, LLV or VF) after VL suppression.  
Another explanation of the relatively low rates of VF in Paper I might be that Newlands 
Clinic aims to provide a standard of care comparable to that of western countries, with routine 
VL monitoring, adherence counselling and social support. Though data from Paper I and 
Paper II are not directly comparable (cross-sectional design, only one VL test was done in 
Paper II), the proportion of "un-suppressed" HIV-infected children and adolescents enrolled 
in a governmental clinic was substantially higher with 69.2% of children having detectable 
viraemia (VL³50 copies/ml) and 36.0% having VL³1000 copies/ml (potentially implying VF). 
This underlines the need for follow-up VL tests, which are seldomly performed due to the 
economical restraints in SSA. 
A number of cohort studies conducted in high-income settings found that detectable 
viraemia is common among individuals on ART and is associated with subsequent VF, yet there 
 48 
is a lack of longitudinal VL data for HIV-infected individuals in RLS (54, 55, 250). In a study 
published in 2018, Hermans et al. claimed to be the first to report on LLV episodes among 
adults on ART in RLS (251), though two prior reports based on data from the Treat Asia HIV 
observational Database (TAHOD cohort) were published earlier in 2014 (252, 253). TAHOD 
cohort includes HIV-infected individuals from low- and middle-income settings in Asia and 
Pacific region (254).  In this cohort the incidence rate of LLV in low- and middle-income 
settings was higher than in our group (0.99 per 100 person-years vs 0.3 per 100 person-years), 
with LLV being a weak predictor of subsequent VF (252). Another paper, which included 1554 
participants from the TAHOD cohort, investigated the predictive value of viral blips. In this 
study blips occurred in 11% of individuals with an incidence rate 31.7 per 1000 person years 
in low- and middle-income settings and no association was found between blips and subsequent 
VF (253). In a large multicenter South African cohort study comprised of data on 70 930 
individuals Hermans et al. demonstrated that LLV occurred in 23% of individuals with an 
incidence rate 11.5 per 100 person-years of follow-up. LLV was also strongly associated with 
subsequent VF in this study (251). The fact that data were collected from 57 rural-urban centres 
with differences in treatment practices over the period 2007-2016 and different sensitivity of 
VL assays used for VL detection may explain the discrepancies between the studies, yet the 
results are indicative of the real-world situation. The authors concluded that thresholds for VF 
for RLS should be reconsidered. Due to very low rates of VF over the study follow-up period 
and relatively short follow-up we could not assess the clinical significance of detectable 
viraemia episodes. 
In the majority of studies (77, 255, 256), children and adolescents have significantly lower 
suppression rates than adults, with children in our study having a 12% lower suppression rates 
and 7 % higher VF rate compared to adults over the follow-up period. This is explained by a 
broad range of challenges during ART treatment in children (83). Poor tolerability to 
antiretroviral drugs, inadequate ART dosing and dependence on a caregiver while 
administering the drug contribute to high rates of detectable viraemia among children (84). 
When reaching adolescence, various psychological, social, environmental issues also come into 
the picture and compromise adherence to treatment and linkage to care even more. Interestingly, 
in our study, seven out of eight children who developed VF during follow-up were aged >10 
years. Notably, a recent study from Malawi show that women with LLV are at higher risk of 
MTCT with the majority of women with LLV in this study being adolescents (257). 
A number of recently published studies show that one of the instruments to improve 
suppression rates in both children and adults is adherence counselling (49, 258, 259). In one 
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study adults who received community-based adherence support had significantly higher 
suppression rates with OR being 1.33 and 2.66 after 1 and 5 years ART, respectively (260). In 
another study, children who received community-based adherence support were also more 
likely to archive VL suppression (OR 1.60) with the most profound effect demonstrated for 
young children with OR 2.47 (261). In Newlands clinic adherence is checked at every visit 
when patients pick up their drugs. During the study period average adherence by pill count was 
98.4% and 99.6% for children and adults, respectively. Our data showing relatively low rates 
of detectable viraemia episodes accompanied by good adherence estimates may indicate that 
more efforts should be moved towards providing adequate routine adherence support for 
individuals on ART. 
To summarize, detectable viraemia among individuals on ART is increasingly recognized 
as a risk factor for multiple AIDS-related problems (increased risk of VF, MTCT, and 
development of HIV drug resistance mutations). In order to reach the third 90 UNAIDS goal, 
more efforts should be put towards increasing adherence and routine VL control. 
 
1.2. Levels of eNO in HIV-infected children  
Advancements in ART lead to a shift of focus in management of HIV infection from 
typical HIV-related opportunistic conditions to less recognized chronic complications. One 
example of this is a disproportionate burden of chronic lung disorders in HIV-infected children 
(136, 137, 139, 166). One might argue about the pathogenesis of those conditions, with TB and 
other chronic infections going hand in hand with HIV, but there is no doubt that the 
aforementioned conditions are a concern in paediatric HIV-infected population.  
Due to the economic restraints of SSA with limited access to modern diagnostic tools, 
data on pathogenesis of lung impairment in this population group are scarce. In Paper II we 
aimed to evaluate the eNO levels in HIV-infected children and adolescents with and without 
history of prior TB.   
Paper II showed that HIV infection is associated with lower eNO levels in children and 
adolescents. To our knowledge, only one study investigated this before.  In a paper published 
in 1997, Loveless et al. reported lower levels of eNO in 36 HIV-infected adults compared to 
relatively healthy hospital staff (262). No studies so far have been conducted in children. The 
other two studies investigated the levels of eNO in individuals with active TB with or without 
HIV-infection. While eNO levels were significantly lower in HIV-infected subjects with active 
TB compared to healthy controls in one study, no association between eNO and HIV status was 
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observed in another one (183, 184). Taken together, these data indicate an effect of both HIV 
and TB on eNO levels, though the clinical importance of this warrants further discussion.  
There are several pathophysiological mechanisms that can explain the observed low eNO 
levels. Several studies show that lower levels of L-arginine (a primary substrate for NO in the 
lung) are observed in individuals with active TB, and may well explain the relative deficiency 
in eNO in those patients (263, 264). On the other hand, no data indicate a lack of L-arginine in 
HIV infection. Dirajlal-Fargo et al. did not find decreased arginine availability in HIV-infected 
ART-treated individuals compared to HIV-uninfected controls (265).   
Despite availability of substrate, the HIV virus may prevent cells from producing 
sufficient amounts of NO. NO is produced by a variety of cells in the respiratory tract, with AM 
being responsible for primary NO release in response to infection (175, 266). HIV persists in 
AM even in individuals with undetectable plasma VL (147, 267, 268). Studies show that 
presence of the virus in AM impairs phagocytic activity of cells and bacterial clearance (146, 
149) There is some evidence that NO has a role in intracellular killing and phagocytic activity, 
though the exact effect of the virus on the NO pathway in AM is unclear (269). Moreover, HIV 
proteins are known to alter the signalling pathways in monocyte/macrophage cells, changing 
the normal response to infection (270). Thus, low NO levels may reflect the AM’s loss of ability 
to produce NO as part of host-defence mechanism and compromised lung immune status. 
Increased catabolism of NO into NO-metabolites is another plausible reason for low eNO 
levels observed in our study. There is evidence that the HIV virus increases the levels of H2O2 
and other reactive oxygen species (ROS) in the alveolar space (149). In the presence of ROS 
(superoxide or H2O2) NO turns rapidly into peroxynitrite and/or stable end products of NO - 
nitrite and nitrate thus lowering the NO gas concentration. Presence of ROS and highly toxic 
peroxynitrite in the lung in turn mediates cell dysfunction and damage of the lung extracellular 
matrix (271, 272). Peroxynitrite is highly unstable and difficult to measure, but may form 
nitrotyrosine (273). Interestingly, studies found high concentrations of nitrotyrosine, nitrate and 
nitrite in sputum and exhaled breath condensate alongside low eNO levels in individuals with 
cystic fibrosis (182, 274-276). As in cystic fibrosis, ongoing oxidative and nitrosative stress in 
the lung during HIV infection may explain low eNO levels in HIV-infected individuals in 
Paper II.  
In addition, low eNO levels could be caused by mechanical factors such as diffusion 
barriers for NO due to increased mucus production or decrease in airway calibre. However, in 
line with other studies (277-280), no association was observed between airway obstruction and 
eNO level in our study population. This indicates that eNO probably has no pathophysiological 
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role in  obstruction, but is rather a marker of the underlying condition, as seen in eosinophilic 
inflammation in asthma patients (281). 
The role of NO during active TB infection has been widely studied. Data show that NO 
activates certain antimicrobial pathways in AM and also limits the pro-inflammatory response 
during TB infection (282). At the same time there is evidence that iNOS may be directly 
inhibited as an immune evasion mechanism by Mtb (283, 284). Two studies reported lower 
levels of eNO in individuals with newly diagnosed untreated lung TB compared to healthy 
controls (183, 184).  
Recent studies showing that Mtb may persist in AM after anti-TB treatment have raised 
interest in post-TB lung complications (155, 285). However, data are scarce regarding NO 
involvement in post-TB lung impairment. Paper II demonstrated that HIV-infected children 
with prior TB in anamnesis had lower eNO compared to HIV-infected children with airway 
obstruction or to HIV-infected with no airway abnormalities. Persistence of Mtb in AM may 
maintain ongoing lung inflammation and accelerate the development of lung fibrosis (155-157). 
Interestingly, in vitro studies found that NO has a protective role in the progression of 
pulmonary fibrosis (286). Thus, low levels of eNO in patients with history of TB may reflect 
altered lung immune status, which further mediates the development of chronic lung 
complications.  
Age was positively associated with eNO levels in both HIV-infected and HIV-uninfected 
participants. It is known that values of eNO increase linearly between 6-16 years in parallel 
with the somatic growth (287). ATS guidelines recommend accounting for age when 
interpreting the eNO results in children younger than 12 years of age (288). A number of studies 
also showed a significant association between height and eNO levels (277, 289-291). Total 
airway mucosal surface area for NO diffusion increases with increasing age and height, thus 
leading to higher eNO levels (292). In Paper II, both age and height were significantly 
associated with eNO levels in HIV-infected children. As these children are generally smaller 
than their HIV-uninfected peers, this may partly explain the lower eNO levels among HIV 
infected children observed in our study.  
In Paper II we did not observe any association between passive smoking and eNO in 
study participants. While a number of studies conducted in healthy children and those with 
asthma showed that passive smoking reduces eNO levels (290, 293, 294), others found no 
correlation between these two parameters (295, 296). Conflicting results regarding the impact 
of passive smoking may be explained by genetic factors. For example, Spanier et al. showed 
that only individuals with specific genetic polymorphisms in the NO synthase gene (namely 
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GT and TT genotypes) have decreased eNO when exposed to passive smoking (297).  
Interestingly, positive associations between several blood parameters and eNO levels 
were observed in Paper II. While a number of studies explored the link between eNO and 
blood eosinophils in asthmatic individuals, data on associations between eNO and other full 
blood count parameters in conditions besides asthma are scarce (181, 183, 298). The 
associations between haemoglobin level, haemotocrit and eNO may reflect physiological 
processes at the level of endothelium. Elevated haematocrit increases shear stress and 
production of NO. The positive association between eNO and blood neutrophils observed in 
HIV-infected participants may be explained by the fact that neutrophils can produce NO in 
response to foreign stimuli (299). The observed associations emphasize the need to interpret 
results with caution and thus question the clinical utility of eNO.  
eNO measurement is emerging as an easy point-of-care test in monitoring of asthma 
patients. Although our study does not give evidence for its utility in RLS as a diagnostic test, it 
provides some important findings. Reduced eNO levels observed in HIV-infected children and 
in those with prior TB are indicative of impaired lung host defence and may mediate increased 
susceptibility to respiratory infections in this population group. Further studies are needed to 
explore pathophysiological pathways that may explain low eNO and what clinical utility it can 
provide - whether it can serve as a marker of chronic lung non-eosinophilic inflammation or 
whether approaches towards increasing NO levels could be beneficial.  
 
1.3. Composition of gut microbiota in HIV-infected children  
In Paper III we investigated the differences in the gut microbiota between HIV-infected 
and HIV-uninfected children, and the association with participant characteristics. Overall, our 
study demonstrated that the gut microbiota in HIV-infected ART-treated children was less 
diverse than in HIV-uninfected controls. However, children who received ART for 10 years or 
more had a more diverse microbiota, resembling that of HIV-uninfected children.  
To the best of our knowledge only one study to date has investigated gut microbiota in 
the paediatric HIV-infected population (225). Kaur et al. demonstrated that alpha diversity was 
significantly lower in HIV-infected children, mirroring the results of our study. Notably, in 
Kaur et al. paper there was no difference in alpha diversity estimates between ART-treated and 
ART-naïve children, though the low sample size (15 participants on ART and 14 ART-naïve) 
of the study does not allow for conclusion with certainty about the effect of ART.  
Studies conducted among adults showed that HIV infection without ART is associated 
with severe intestinal dysbiosis and reduced alpha diversity (29, 208, 300). These changes may 
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persist despite ART (5, 6, 10, 38, 39). A recently published individual level meta-analysis 
comprising data from 17 datasets on 1032 individual samples also demonstrated that HIV 
infection in adults is associated with decreased alpha diversity of gut microbiota (301). Our 
results of overall lower alpha diversity in HIV-infected ART-treated children support and 
extend these findings.   
The data are less consistent when it comes to relative abundance of specific taxa in HIV-
infected individuals. Such factors as different types of specimens used (stool samples, rectal 
swabs, etc), study populations, geographical area, sequencing methods and false discovery may 
explain these discrepancies (302, 303). Kaur et al. studied fecal microbiota and reported 
significantly higher relative abundance of Prevotella in both ART-treated and ART-naïve 
children compared to HIV-uninfected controls (225). This is in contrast to our findings where 
HIV-uninfected participants were enriched in Prevotella. A few possible explanations exist – 
the study sample size, different diet and geographical location are certain to influence the 
microbiome composition (303). Another point is that Kaur et al. used fecal samples, while we 
used rectal swabs. A study on rectal swabs of HIV-infected ART-treated participants in Nigeria 
reported higher abundance of Finegoldia and Anaerococcus, which is consistent with our 
findings (304). However, in the same study Campylobacter was significantly enriched in HIV-
infected participants, in contrast to our findings of enriched Campylobacter in the HIV-
uninfected group.   
The effect of ART on gut microbiota composition is contradictory. At least two studies 
have found a negative impact of ART on gut biodiversity (208, 305). In a longitudinal study, 
Nowak et al. demonstrated a decrease in gut microbiota diversity after the introduction of ART. 
Our results are not in direct contradiction to this study, as Nowak et al. investigated the effect 
of ART initiation, with a relatively short follow-up of 10 months (208). In Paper III we had 
no ART-naïve children, and the minimum duration of ART was 1 year. We observed lower 
alpha diversity in those who were on ART for less than 10 years compared to HIV-uninfected 
participants.  
A number of studies conducted among individuals on long-term ART reported gut 
microbiota diversity estimates similar to HIV-uninfected participants (218, 300). For example, 
Dinh et al. found no significant difference in alpha diversity measures between HIV-infected 
participants who were on suppressive ART for a median of 13.3 years and HIV-uninfected 
controls (218). This is similar to our findings for children who received ART for 10 years or 
more. The impact of ART duration on the gut microbiota was also acknowledged in another 
study where individuals with longer ART duration showed a closer resemblance to HIV-
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uninfected group than to subjects with untreated HIV infection (306). These studies together 
with our findings indicate the ability of ART to restore the altered gut microbiota in the long 
run. 
We did not find a link between CD4 count and gut microbiome diversity indices, yet there 
was a weak negative association between VL>1000 copies/ml and Chao1 index. A number of 
studies showed significantly lower microbiome diversity in those with more severe HIV status 
(208, 307). However, the findings of previous studies may have been affected by sample size 
and duration of ART. A longitudinal study with repeated measurements of VL, CD4 and 
microbiome profiles is needed to uncover the relationship between these parameters.  
We found enriched levels of Enterobacteriaceae in HIV-infected participants with low 
CD4 cell counts, a finding that was also reported in HIV-infected adults with pneumonia in 
Uganda (308). Enterobacteriaceae are part of the normal intestinal flora, though our finding 
may explain the high incidence of gastrointestinal and urinary tract infections caused by 
Enterobacteriaceae in HIV-infected children (309). Burkholderiaceae was also enriched in 
those with low CD4 cell counts, including the species known to cause severe lung infections in 
patients with cystic fibrosis (310).  
A number of recently conducted studies investigated the gut dysbiosis in relation to 
chronic HIV-associated complications (222, 224). Hoel et al. found the lowest alpha diversity 
estimates in HIV-infected participants who also had a diagnosis of type 2 diabetes, while no 
difference was noted between HIV-infected subjects with no diabetes and healthy controls 
(222). Another study found no difference in alpha diversity indices between HIV-infected 
adults with and without metabolic syndrome (224).  
Recent years have been characterized by increasing interest in the role of gut microbiome 
in lung health and lung disease (311). Gut dysbiosis has been reported in HIV-uninfected 
individuals with lung disorders (202, 203). Notably, a recent study demonstrated a link between 
the gut and the lung microbiota composition in HIV-infected individuals with bacterial 
pneumonia. Moreover, this study found an association between lower gut microbiota diversity 
and mortality (308). The exact mechanism for this is yet to be discovered, though one might 
speculate that the decrease in normal flora might affect the susceptibility to infections, as well 
as disturb the normal metabolism in the gut. There is also some evidence from a murine model 
that gut microbiota enhances alveolar macrophage function and has a protective role during 
pneumococcal pneumonia (312).  
In Paper III we did not observe an association between CLD or history of prior TB and 
alpha diversity estimates, though there were some significant differences in relative abundance 
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of specific taxa. For example, the genus Faecalibacterium was enriched in HIV-infected 
individuals with CLD while the genus Prevotella was enriched in HIV-infected children 
without CLD.  Interestingly, higher proportions of Prevotella have previously been shown in 
lung microbiota of children without asthma compared to asthmatic children and adults with 
COPD (313). Faecalibacterium has previously been regarded as a protective commensal 
associated with a healthy gut. However, a recent study showed increased levels of 
Faecalibacterium in the gut microbiome of patients with active TB (314). The importance of 
this finding is unclear, being either a fluke or a protective mechanism, and further studies are 
warranted if we want to say with certainty whether there is a causal relationship between the 
gut and the lung. 
Our study is one of the largest to assess the gut microbiota of HIV-infected children and 
adolescents in a high HIV-burden setting. Our findings demonstrate altered gut microbiota in 
perinatally HIV-infected individuals, which improves with increasing time spent on ART. 
Further studies where the gut and lung microbiota and markers of microbial translocation and 
inflammation are measured are necessary in order to provide better insight into the role of gut 
microbial composition in HIV progression and its related complications.  
 
2. Methodological considerations 
The current work is comprised of the findings of three studies, all performed in HIV-
infected individuals living in SSA. However, the populations and study designs vary between 
the studies. In this chapter I have tried to summarize both the positive and the negative aspects 
of the different study designs used, as well as certain limitations to the methods employed. 
 
2.1. Study designs 
The present work is based on observational studies. The choice of study design depends 
on the research question and available resources. Observational studies allow for the 
investigation of the "natural course" of risk factors and outcomes (diseases) without any 
interventions. These studies are practical, relatively inexpensive and quick, allowing 
researchers to study conditions with a long latent period (315). Observational studies include 
cohort, cross-sectional and case-control studies. In the present work, cohort and cross-sectional 
designs were utilized. 
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Cohort study design 
Cohort studies follow individuals over time and allow investigation of the aetiology of 
the event (study outcome), associations between exposure and outcome as well as estimation 
of both absolute and relative risks. Absolute risks include incidence rates and cumulative risks 
which are estimated from the number of new cases in a study population within a given time 
period (316, 317).  
In cohort studies exposures are identified before the outcome (VF, disease, death) 
happens, thus allowing for the assessment of causality. Another advantage is the opportunity to 
investigate multiple exposures and multiple outcomes in a single cohort. In addition, compared 
to RCT, cohort studies generally have broader inclusion criteria and fewer exclusion criteria 
and therefore may produce more generalizable results (317).   
Cohort studies may be prospective or retrospective. Prospective cohort studies allow 
more accurate data collection but are expensive and time consuming (since long follow-up is 
usually required). Prospective cohort studies are not appropriate when there is a long latent 
period between exposure and outcome and for rare events due to the high risk of loss to follow-
up. On the other hand, retrospective cohort studies are inexpensive and time-efficient as data 
are already available (318). Given the relatively low rate of detectable viraemia episodes 
observed over the follow-up period in Paper I, we believe that retrospective observational 
study design was the most appropriate option.  
 
Cross-sectional study design  
Cross-sectional design allows for the estimation of prevalence (number of cases in the 
population at a given point of time) and the study of multiple outcomes. In cross-sectional 
studies the data on disease and exposure are collected at one particular time point and therefore 
temporal relationship between exposure and study outcome cannot be established (317, 319). 
Even though no causal relationship can be stated, the investigators may formulate questions in 
a way that the subject is asked about his/her previous exposures (treatment for a disease, 
lifestyle, etc), thus making room for extrapolation of the previous exposures as a possible cause 
for the outcome. This allows for categorization of subjects based on previous exposures even 
if the information is collected at one point in time. Since multiple risk factors and outcomes can 
be assessed, these studies may be particularly useful for understanding disease aetiology and 
for hypothesis generation. The associations observed in cross-sectional studies may be 
investigated in more detail in cohort studies or RCT. Given the exploratory nature of studies in 
Paper II and III, we believe that cross-sectional design was the most appropriate.  
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2.2. Internal validity and technical limitations 
Research studies are evaluated in terms of internal and external validity. Internal validity 
refers to how well the study was conducted and depends on the degree to which bias is 
minimized (320, 321). Bias is a systematic error which may occur at any stage of conducting a 
study, including study design and data collection, as well as analysis and publication (322). The 
presence of selection bias, information bias, or confounding may lead to inaccurate estimates 




Selection bias occurs when the participants selected for a study are systematically 
different from eligible participants who are not selected for the study (321). Therefore, the study 
population does not represent the target population for which a statement (conclusion) is to be 
made. Selection bias may occur at the study enrolment or retention of participants in the study 
(for example when those who were exposed to a certain factor are less likely to be followed 
than those in the unexposed group). The latter is relevant for cohort studies and is usually 
referred to as “differential loss to follow-up”. 
Data for Paper I was collected in a not-for-profit clinic which provides care to an 
unselected population of more than 6500 HIV-infected individuals in Harare. The 
demographical profile of study participants was comparable to the country’s HIV profile, 
suggesting that the study participants are representative of the population at risk. For Paper II 
and III, participants were recruited in Harare central hospital, a government funded hospital, 
which has a catchment area of 1.5 million residents and provides care for around 3500 HIV-
infected children.  
 
Information bias  
Information bias occurs when data are measured or recorded inaccurately resulting in a 
misclassification of exposure and/or outcome. Two types of misclassification may occur: 
differential and nondifferential. Nondifferential misclassification occurs when the degree of 
misclassification of exposure among those with and without outcome (disease) is the same (321, 
323). This will bias results towards the null hypothesis (no association) in the case of binary 
exposure variables. Differential misclassification occurs when the degree of misclassification 
is different between the compared groups and may bias estimates in any direction. The latter is 
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especially likely when the information on exposure is recorded after the outcome occurred. 
Recall bias, measurement error, and technical limitations usually contribute to information bias. 
 
Recall bias  
Differential misclassification may be introduced into the study as a result of recall bias. 
It occurs when the participants’ ability to recall past exposures depends on the outcome status. 
Recall bias is usually a minor concern in cohort studies due to the temporal sequence of the 
exposure and outcome. However, it is a common issue in studies that use self-reported 
information. Self-reporting (use of questionnaires, surveys, interviews) is a common approach 
to collect information about participants (320, 321). It is generally acknowledged that self-
reporting is a less reliable approach for gathering information about participants than medical 
records.  
The risk of recall bias in Paper I is low since data were extracted from medical records. 
In Paper II and III, clinical data were collected via questionnaires that were administered after 
the participant's airway obstruction was diagnosed by spirometry. Therefore, differential 
misclassification of exposure could be the introduced when participants were classified into 
groups based on history of TB. It is possible that those who were found eligible for the trial 
could overreport prior TB in anamnesis while those with normal lung function could 
underreport prior TB. A reasonable approach to minimize the risk of recall bias could be 
verification of exposure information by review of hospital or pharmacy records, though this 
was not feasible in the given setting.  
 
Measurement error bias 
Lack of accuracy, precision and/or reliability of procedures performed refers to 
measurement (instrument) error and may also cause misclassification (324). A number of 
measurement techniques were used in the present work. 
 
HIV VL measurement 
In Paper I HIV VL was detected using an FDA-approved Roche COBAS AmpliPrep / 
COBAS TaqMan48 version 2.0 assay which has high sensitivity and specificity (325). In Paper 
II and III, point-of-care GeneXpert VL assay was used. It shows good precision on plasma 
samples and good correlation with reference assays (326, 327).  For WHO prequalification 
Xpert HIV-1 VL assay had 94.1% sensitivity and 98.5% specificity for VF at 1000 copies/ml 
(328). 
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Measurement of eNO 
In Paper II we used NIOX VERO, a portable device to measure eNO levels. It was shown 
to have better reproducibility and reliability compared to the chemiluminescence technique (the 
gold standard for eNO measurement) (329, 330). Measurements were performed according to 
ATS guidelines (229) and the same instrument was used in order to standardize measurement 
conditions. 
 
Use of FEV1 z-scores instead of predicted values 
In Paper II and III we used FEV1 z-scores instead of predicted values for interpreting 
spirometry results. The advantage of using z-scores is that it takes into account the underlying 
distribution of normal lung function data when classifying the estimated values into the severity 
categories of lung impairment. This approach eliminates biases due to age, height and sex 
differences in underlying lung function distribution when using FEV1 %predicted (165).  
 
Use of rectal swabs for gut microbiota analysis 
Rectal swabs were used as specimens for sequencing in Paper III. Swabs are relatively 
low biomass samples which may not be optimal with regards to profiling the gut microbiota. 
However, a number of studies showed good concordance between the use of rectal swabs and 
solid stool samples for profiling and comparisons of the gut microbiota (331, 332).  
 
Confounding 
Confounding is a situation when an apparently causal association observed between the 
exposure and an outcome is due to the influence of the third variable (or variables). A 
confounder must fulfil certain criteria: 1) it is related to both exposure and outcome; 2) it is 
unequally distributed between the study groups; 3) not part of the causal pathway between the 
exposure and the outcome (321). Confounding can be addressed by statistical approaches such 
as stratification or multivariable modelling (where confounders are included as covariates in 
multivariable regression models) (333). 
In Paper I, age, sex and baseline CD4 count were considered as the most likely 
confounders. Therefore, the analyses were performed separately for children and adults and 
age, sex and baseline CD4 count were adjusted for. Age, sex and the time of the day when the 
measurement was performed may influence eNO level and were the factors we adjusted for in 
Paper II. When investigating gut biodiversity in Paper III, age, sex and BMI were adjusted 
for. 
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Unmeasured confounding may decrease the validity of the findings. There are a number 
of parameters that were not assessed in Paper II and III and which could have affected the 
study outcomes (eNO or gut microbiota). For example, among parameters which may influence 
eNO levels and which were not assessed in the Paper II are genetic factors (activity of NO 
synthase) and environmental factors (air pollution). In Paper III we did not assess diet and 
social factors such as housing or level of education of the participants, which could also have 
an impact on gut microbiota.  
 
2.3. External validity 
External validity refers to the generalizability of the results (whether the study 
conclusions will hold for other subjects, places and times). The closer the recruited subjects are 
to the target population the better the external validity.  Adequate internal validity is a 
prerequisite for external validity (319, 321). Despite certain limitations mentioned above, we 
believe that the results of Paper I can be generalized to HIV-infected individuals living in HIV 
high-burden countries. External validity of Paper II and III findings may be limited to African 





Conclusions and future perspectives 
More than half of HIV-infected adults and two-thirds of HIV-infected children reside in 
Eastern and Southern Africa. Despite limited healthcare resources, our study demonstrated that 
adequate VL suppression is an achievable and realistic goal even for this area.  The rates of VL 
suppression following ART initiation observed in Paper I are close to the third “90” UNAIDS 
goal (90% of those on ART treatment have suppressed VL). At the same time, our study 
revealed that more children than adults fail to reach VL suppression and are more prone to 
experience detectable viraemia after initial VL suppression. High rates of detectable viraemia 
observed in Paper II-III also support insufficient VL suppression in paediatric HIV-infected 
population. 
Given that detectable viraemia is the main driver of HIV progression and transmission, 
our results emphasize the need to prioritize routine VL monitoring in the paediatric population 
in areas where access to VL testing is limited. Development and implementation of specific 
programs oriented towards young individuals growing up with HIV is justified in order to 
improve virological outcomes and reduce the risk of HIV transmission. The significance of 
detectable viraemia episodes in RLS requires further studies.  
As the result of improved survival, a growing number of HIV-infected individuals on 
ART develop chronic comorbidities. Recent evidence indicates that HIV-infected children and 
adolescents are at increased risk of lung disorders. However, to date, few studies have focused 
on pathological pathways that may be involved in lung impairment in this population group. 
Paper II showed that both HIV infection and prior TB are associated with lower eNO levels, 
an important component of lung host defence.  
Whether approaches to increase NO levels may be beneficial in this group or whether 
measurement of eNO may be useful in management of long-term lung complications in HIV-
infected individuals needs further investigation. At the same time, certain recommendations 
may be given already now. In light of the high burden of lung impairment in HIV-infected 
ART-treated children in SSA, monitoring of lung health in this group is warranted. There is a 
need to adapt care delivery services in a way that early detection of these chronic comorbidities 
becomes feasible. In addition, in light of the persistently high incidence of TB in ART-treated 
individuals, development of joint longitudinal HIV and TB care programs would be beneficial 
for management of long-term lung impairment.  
The present work demonstrated that perinatally acquired HIV infection is associated with 
altered gut microbiota, which improves with increasing duration of ART. Further studies 
assessing microbial translocation markers, immune activation, and microbe-derived 
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metabolites are needed to find out what implication gut dysbiosis may have on HIV disease 
progression. Though we did not observe an association between gut biodiversity and presence 
of lung impairment, studies where both gut and lung microbiota are investigated simultaneously 
may uncover potential links between these sites. Future studies are warranted to find out 
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A B S T R A C T
Objective: To investigate the incidence and predictors of viraemia among individuals on antiretroviral
therapy (ART) in Harare, Zimbabwe.
Methods: Children (0–19 years) and adults (>19 years) starting ART between 2013 and 2015 were
followed for a median of 2.8 and 2.7 years, respectively. The incidence rates of virological failure (VF),
low-level viraemia (LLV), and viral blips were assessed and the predictors of viraemia were determined
using logistic and parametric survival regression analyses.
Results: A total of 630 individuals initiated ART, and 19.7% of children and 5.6% of adults did not achieve
viral suppression by 12 months. Younger age and CD4 count 200 cells/mm3 at baseline were associated
with not being virally suppressed at 12 months in adults. Among those who achieved viral suppression
during the follow-up period, the incidence of VF was higher in children (4.0/100 person-years vs. 0.4/100
person-years in adults; p < 0.001), as was the incidence of LLV (1.9/100 person-years vs. 0.3/100 person-
years in adults; p = 0.03). The incidence rate of blips was 10.9 per 100 person-years in children and 4.0 per
100 person-years in adults.
Conclusions: Children are less likely to reach viral suppression and are at higher risk of viraemia while on
ART than adults. The significance of LLV and blips needs further study.
© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal home page: www.elsevier .com/ locat e/ i j idIntroduction
Access to antiretroviral therapy (ART) has substantially
increased survival and improved quality of life for HIV-infected
individuals worldwide (Antiretroviral Therapy Cohort C, 2017; De
La Mata et al., 2016). Sustained viral suppression achieved on ART
reduces the risk of immunodeficiency, clinical progression, and
HIV transmission (Cohen et al., 2016). According to World Health
Organization (WHO) guidelines, an HIV viral load (VL) of 1000
copies/ml should prompt enhanced counselling and a repeat VL* Corresponding author at: Department of Community Medicine, Faculty of
Health Sciences, UiT—The Arctic University of Norway, Hansine Hansens veg 18,
9019 Tromsø, Norway.
E-mail address: evgeniya.sovershaeva@uit.no (E. Sovershaeva).
https://doi.org/10.1016/j.ijid.2018.10.019
1201-9712/© 2018 The Authors. Published by Elsevier Ltd on behalf of International Soc
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).test within 6 weeks, and two sequential VL measurements of
1000 copies is considered virological failure (VF) and should lead
to regimen change (World Health Organization, 2016).
A proportion of individuals on ART experience low-level
viraemia (LLV) and/or transient viraemia; for example, viral blips
have been reported in up to 40% of HIV-positive individuals on ART
(Grennan et al., 2012; Havlir et al., 2001; Sorstedt et al., 2016). Viral
blips have been shown to be associated with higher HIV pre-
treatment VL and lower CD4 count at the time of ART initiation
(Farmer et al., 2016; Havlir et al., 2001; Sorstedt et al., 2016). There
is some evidence that they may impair CD4 cell recovery and
maintain ongoing low-grade immune activation (Taiwo et al.,
2013; Zoufaly et al., 2014).
Data on detectable viraemia after ART initiation are scarce and
particularly the incidence and significance of transient and/or LLV
in low-income settings, where – unlike high-income settings –iety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
66 E. Sovershaeva et al. / International Journal of Infectious Diseases 78 (2019) 65–71regular VL monitoring is not the norm (Haas et al., 2015). The few
studies that have been conducted in low-income countries have
focused mainly on adults (Kanapathipillai et al., 2014). However,
children are potentially at a higher risk of developing viraemia due
to weight-based dosing, which may lead to variable drug levels,
poor tolerability of drugs, and suboptimal adherence (Easterbrook
et al., 2002; Young et al., 2015). Moreover, psychosocial factors
including dependence on a caretaker and delayed disclosure of HIV
status to the child may put children at higher risk of remaining
viraemic after ART initiation (Lall et al., 2015). Adolescence is a
specific high-risk period for poor adherence in many chronic
conditions (Taddeo et al., 2008).
In this study, the incidence of and risk factors for detectable
viraemia including VF, LLV, and blips were investigated in a cohort
of HIV-infected children and adults initiated on ART in Harare,
Zimbabwe.
Methods
A retrospective cohort study was conducted using data
collected from patients who attended Newlands Clinic, Harare,
Zimbabwe, a not-for-profit HIV clinic that provides care for
children and adults. ART is provided free of charge according to
national guidelines. Routine 6-monthly VL monitoring is per-
formed (during the study period, this was done using the Roche
COBAS AmpliPrep/COBAS TaqMan48 version 2.0 test; Roche
Molecular Systems, Pleasanton, CA, USA). Adherence and psycho-
social counselling is provided at each clinic visit (at least every 3
months). Adherence is assessed by pill count for each antiretroviral
drug at every clinic visit. In the case of suspected VF (a VL
1000 copies/ml), the patient receives intensified adherence
counselling for 6 weeks and repeated VL testing. Those with a
VL  1000 copies/ml in two consecutive VL measurements are
considered to have VF and are switched to second-line ART
(protease inhibitor (PI)-based regimen and change of at least one
nucleoside reverse transcriptase inhibitor (NRTI)). Those on
second-line ART who have a VL 1000 copies/ml despite
counselling undergo HIV drug resistance testing and are consid-
ered for third-line ART.
Individuals who were ART-naïve and initiated ART between
August 2013 and August 2015 and who had at least two VL tests
after ART initiation were included in the study. The following data
were extracted: age, sex, date of ART initiation, ART regimen,
adherence, height, weight, clinical history (WHO HIV disease stage,
history of tuberculosis, opportunistic infections, chronic comor-
bidities), and laboratory parameters (VL, CD4 count, haemoglobin)
at the time of ART initiation and during the follow-up period until
September 28, 2017.
Data analysis
All patient data are stored in a secure electronic database. The
data were anonymized prior to analysis. Statistical analyses were
performed in Stata 14 (StataCorp LLC, College Station, TX, USA). The
outcomes were the incidence of VF, LLV, and viral blips. Viral blip
was defined as a VL measurement 50 copies/ml preceded and
followed by a VL below the limit of detection (<50 copies/ml)
(Havlir et al., 2001; Kanapathipillai et al., 2014; Martinez et al.,
2005). LLV was defined as a VL 50 to <1000 copies/ml in at least
two consecutive VL tests. The WHO definition for VF was used (VL
1000 copies/ml in two consecutive VL measurements) (World
Health Organization, 2016).
The proportion of participants who did not achieve viral
suppression by 12 months of ART (the 12-month cut-off was
chosen to allow for a VL test to confirm suppression at month 12)was estimated and the factors associated with virological non-
suppression were studied using logistic regression.
The incidence rates of viral blips, LLV, and VF among those who
had achieved viral suppression during the follow-up period and
had at least two VL tests after initial VL suppression were
estimated. Nelson–Aalen cumulative hazard curves were plotted to
evaluate the incidence of VF, LLV, and viral blips after VL
suppression by age at ART initiation (children aged 0–19 years
and adults aged >19 years).
The factors associated with the occurrence of viral blips were
investigated using survival analysis. For the model, participants
were included in the analysis at time 0 (time of first suppressed VL
test after ART initiation) and followed until a viral blip occurred, or
for those patients who remained suppressed until the last VL test
available, by the end of the follow-up. Participants who reported
treatment interruption in ART for more than 2 weeks were
excluded from this analysis. Since the estimated cumulative hazard
of blips increased exponentially with time, we fitted the
parametric survival regression with Weibull distribution stratified
by age group. A value of P (the shape parameter) >1 confirmed that
the hazard of failure (viral blip) increased with time.
Age, sex, body mass index (BMI), stunting (in children only),
pre-treatment VL, CD4 count, anaemia, WHO clinical stage at ART
initiation, history of tuberculosis before ART initiation, chronic
comorbidities (adults only), ART regimen, and average adherence
were investigated as predictors of detectable viraemia. Stunting
was defined as a height-for-age Z-score of <2 (children only).
Height-for-age Z-scores and BMI-for-age Z-scores in children were
calculated using WHO reference standards. Anaemia was defined
according to WHO criteria (haemoglobin <11 g/dl for children <5
years; haemoglobin <11.5 g/dl for children 5–11.99 years; haemo-
globin <12 g/dl for children 12–14.99 years; haemoglobin <12 g/dl
for females aged 15 years; haemoglobin <13 g/dl for males aged
15 years). Adherence was calculated as a percentage of the
number of tablets dispensed at the last visit minus the number of
tablets returned at the current visit divided by number of tablets
that should have been consumed between visits. The average
adherence over the study period was calculated for each
participant. Age, sex, and CD4 count were adjusted for a priori.
All statistical tests were two-tailed and p-values of <0.05 were
considered statistically significant.
Ethical approval for the study was obtained from the Newlands
Clinic Research Committee, the Medical Research Council of
Zimbabwe, and Regional Committee for Medical and Health
Research Ethics (Norway).
Results
Of the 725 participants who initiated ART during the study
period, 17 were excluded as they were suppressed at baseline (and
thus may have received ART previously) and 78 were excluded for
having <2 VL measurements available following ART initiation
(Figure 1). The baseline demographic, clinical, and laboratory
characteristics of the remaining 630 participants (127 children and
503 adults) are shown in Table 1. The median follow-up time was
2.8 (interquartile range (IQR) 2.3–3.2) years for children and 2.7
(IQR 1.8–2.8) years for adults. The sex distribution was equal in the
paediatric group (49.6% female vs. 50.4% male), while there were
more adult female than male participants (62.2% female vs. 37.8%
male), consistent with studies in Sub-Saharan Africa, which have
shown higher HIV treatment coverage among women (UNAIDS,
2013). Twenty-one children, all aged below 3 years at ART
initiation, were commenced on PI-based regimens, as per the
national guidelines, which recommend PIs as part of the first-line
regimen in children below 3 years. Ten adults initiated treatment
with a PI-based regimen based on clinician judgement, with
Table 1
Characteristics of study participants. Results are presented as the number (percentage), or as the median (interquartile range), unless indicated otherwise.
Characteristics Children (n = 127) Adults (n = 503)
Demographic
Male 64 (50.4%) 190 (37.8%)
Age at ART initiation, years 10 (3–15) 37 (31–44)
Stunted at ART initiation (height-for-age Z-score <2) 24 (18.9%)
Underweight at ART initiation (BMI Z-score <2 for children or BMI <18.5 kg/m2 for adults) 13 (10.2%) 40 (8.0%)
Clinical
History of tuberculosis 10 (7.9%) 59 (11.7%)
Prevalence of chronic comorbiditiesa 2 (1.6%) 90 (17.9%)
Opportunistic infectionsb 13 (10.2%) 75 (14.9%)
WHO clinical stage 3 or 4 at ART initiationc 31 (24.8%) 144 (28.9%)
ART regimen at treatment initiation
2NRTI + NNRTI 106 (83.5%) 493 (98.0%)
PI-based 21 (16.5%) 10 (2.0%)
Average adherence to ART by pill-count 98.4% 99.6%
Years on ART 2.8 (2.3–3.2) 2.8 (1.8–2.8)
Laboratory
CD4 count at ART initiation, cells/mm3 341 (137–733) 220 (104–334)
Viral load at ART initiation, log10 copies/mld 4.8 (4.4–5.3) 4.8 (4.3–5.2)
Anaemia at ART initiation 82 (64.6%) 248 (49.4%)
ART, antiretroviral therapy; BMI, body mass index; WHO, World Health Organization; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor.
a Chronic comorbidities included hypertension, diabetes, or renal failure diagnosed before inclusion in the study.
b After ART initiation, had at least one episode of one of the following: oral candidiasis, necrotizing gingivitis, herpes zoster, histoplasmosis, cryptococcal meningitis,
molluscum contagiosum, genital warts, tonsillitis.
c Data missing for two children and five adults.
d Data missing for 42 children and 159 adults.
Figure 1. Flow chart of participant recruitment.
E. Sovershaeva et al. / International Journal of Infectious Diseases 78 (2019) 65–71 67reasons including severe anaemia, Kaposi sarcoma, WHO stage 4,
third trimester of pregnancy, and breastfeeding.
Of the 630 participants, significantly more children than adults
did not achieve viral suppression by 12 months post ART initiation
(19.7% children vs. 5.6% adults; p < 0.001). Younger age and CD4count 200 cells/mm3 at baseline were associated with not
achieving viral suppression in adults (Table 2). Over the follow-
up period, 106 (83.5%) children and 482 (95.8%) adults reached VL
suppression, with the median time to VL suppression being 0.5 (IQR


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































68 E. Sovershaeva et al. / International Journal of Infectious Diseases 78 (2019) 65–71Of the 588 participants who achieved viral suppression after
ART initiation, 516 had sufficient VL data to study the incidence of
detectable viraemia. Over the follow-up period, 57 (11%) partic-
ipants experienced a viral blip. Blips occurred more commonly in
children than in adults (22.9% vs. 8.3%; p < 0.001), with the
incidence rate being 10.9 (95% confidence interval (CI) 7.2–16.6)
per 100 person-years in children and 4.0 (95% CI 2.8–5.5) per 100
person-years in adults (Figure 2A). Fifty percent of blips in children
and 71.4% of blips in adults were of low magnitude (50–199 copies/
ml). The median time from viral suppression to a blip was 1.9 (IQR
1.4–2.3) years in children and 1.8 (IQR 1.0–2.1) years in adults.
Seven (1.4%) participants (four children and three adults)
experienced LLV and 12 (2.3%) participants (eight children and four
adults) developed VF after initial suppression during follow-up.
The incidence of LLV was 1.9 (95% CI 0.7–5.1) per 100 person-years
in children and 0.3 (95% CI 0.1–1.0) per 100 person-years in adultsFigure 2. Nelson–Aalen cumulative hazard curves for the development of (A) viral
blips, (B) low-level viraemia (LLV), and (C) virological failure (VF) after viral load
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































E. Sovershaeva et al. / International Journal of Infectious Diseases 78 (2019) 65–71 69(Figure 2B). VF was more common in children compared to adults
(8.3% vs. 0.9%; p < 0.001). The incidence of VF was 4.0 (95% CI 2.0–
7.9) per 100 person-years in children and 0.4 (95% CI 0.2–1.2) per
100 person-years in adults (Figure 2C). Notably, 2.2% of children
<10 years and 13.7% of those 10 years developed VF (p = 0.05). All
four adults with VF had re-suppression (three following a switch
from a non-nucleoside reverse transcriptase inhibitor (NNRTI)-
based to a PI-based regimen, one remaining on the same NNRTI-
based regimen), while only three children had re-suppression (two
following a switch from an NNRTI-based to a PI-based regimen,
one remaining on the same NNRTI-based regimen) during the
follow-up period.
Four out of 22 children (18.2%) experienced both viral blips and
VF during the follow-up. Blips were followed by VF in two
participants, while blips occurred after VF and re-suppression in
the other two cases. In those participants with blips followed by VF,
the magnitude of blips was low, while in those who had blips after
VF, blips were of medium (200–499 copies/ml) and high
(>500 copies/ml) magnitude. Among two children with blips after
VF, one had re-suppression on the same ART regimen with
adherence counselling, while another had re-suppression after a
switch to a PI-based regimen. Two children with blips followed by
VF remained unsuppressed by the end of follow-up.
Due to low rates of LLV in the study participants after initial VL
suppression, risk factors for only viral blips were investigated in
the survival analysis. The survival analysis included 507 partic-
ipants (94 in the paediatric group and 413 in the adult group). No
baseline characteristics were found to be associated with an
increased risk of viral blips in children or adults (Table 3).
Discussion
Among individuals starting ART, a significantly higher propor-
tion of children compared to adults did not achieve viral
suppression by 12 months. Likely reasons include poor tolerability
to antiretroviral drugs, inadequate ART dosing, or suboptimal
adherence (Boerma et al., 2016). This is in line with the findings of
Jobanputra et al., who showed that being a child or adolescent is
associated with detectable viraemia (Jobanputra et al., 2015). Some
individuals may require longer periods to achieve suppression, as
shown in the present study, where over the follow-up period,
83.5% of children and 95.8% of adults did achieve viral suppression.
One possibility is that perinatally HIV-infected young children tend
to have sustained high VL in the first years of life with slow
reduction of peak VL with increasing age (McIntosh et al., 1996).
This potentially could contribute to incomplete initial VL
suppression and a higher risk of viraemia. Yet the present study
results do not support this, as the exclusion of children aged 3
years did not change the rates of viral non-suppression in the
paediatric study group. Lower CD4 count at baseline was
associated with not being suppressed at 12 months in adults, a
finding consistent with other studies (Anude et al., 2013;
Collaboration of Observational et al., 2008; Mujugira et al.,
2016; Samuel et al., 2014).
This study found a significantly higher incidence of viral blips
among children compared to adults. The reported incidence of
blips varies in different populations (Farmer et al., 2016; Grennan
et al., 2012; Havlir et al., 2001; Kanapathipillai et al., 2014; Sorstedt
et al., 2016), largely due to different definitions and variability of
the assays for VL. We used a common definition of viral blip, as a
single VL measurement 50 copies/ml preceded and followed by
VL <50 copies/ml (Fung et al., 2012; Ryscavage et al., 2014).
Compared to studies that have used a similar definition, it was
found that a lower proportion of adults in the present study
experienced blips: 8.3% during 2.1 years of follow-up compared to
18.6–40% followed up from 1.08 to 1.58 years (Havlir et al., 2001;
70 E. Sovershaeva et al. / International Journal of Infectious Diseases 78 (2019) 65–71Martinez et al., 2005; Sklar et al., 2002). Several studies have
shown that patients on PI regimens are more prone to developing
viral blips (Grennan et al., 2012; Sorstedt et al., 2016). Havlir et al.
(2001) reported a high incidence of blips (40%) in a cohort of
patients who received an unboosted PI-based treatment regimen
in a high-income country. In addition, the median number of VL
measurements was 17 per participant, compared to an average of
six measurements in the present study in which only 2.1% of adults
were receiving a ritonavir-boosted PI-based regimen.
It is likely that more frequent VL testing will increase the
probability of detecting blips, which may explain the discrepancies
between our findings and those of studies conducted in high-
income settings. However, in a study comparing the incidence of
blips in high-, middle-, and low-income countries, 21% of the
individuals in the first category experienced blips, while only 11%
of participants did so in the middle/low income group, despite a
similar ratio of blips to the number of VL measurements across the
settings (Kanapathipillai et al., 2014). HIV plasma RNA measure-
ments are subject to pre-analytic and laboratory errors, variations
in cut-off point, and variations in lower limit of detection among
the different VL assays, which may have an impact on the incidence
of blips (Grennan et al., 2012; Young et al., 2015). Even though good
agreement between the different assays is observed at high VL
levels, there is substantial variability at low VL levels (Ruelle et al.,
2012; Swenson et al., 2014a).
There appear to be limited data on the incidence of viral blips in
children in the low-income setting (Jobanputra et al., 2015; Szubert
et al., 2017). In a retrospective analysis of VL tests among children
who initiated ART in Uganda and Zimbabwe, 46% of children
experienced viral blips (Szubert et al., 2017). This is considerably
higher than the results of the present study, but may be explained
by the use of WHO 2006 criteria for ART initiation, which relied on
clinical and/or immunological assessment and not just the
diagnosis of HIV infection. The majority of studies in low-income
countries have investigated the incidence of any detectable
viraemia in one or two VL measurements. For example, a cross-
sectional study among adolescents with HIV conducted in an urban
setting in Cameroon utilized two consecutive VL measurements to
detect sustained VL suppression (VL < 50 copies/ml in two VL tests)
(Fokam et al., 2017). In that study, 18.6% of participants had a VL
measurement above 50 copies/ml in a single test. Another study
conducted in Ethiopia found detectable viraemia (defined as an
HIV-1 RNA of 41–1000 copies/ml) in a single VL measurement in
13% of HIV-positive children who had received first-line ART for a
median of 24 months (Mulu et al., 2014). In a study by Jobanputra
et al., 38% of children aged <10 years and 34% of children aged 10–
19 years had single detectable VL (>100 copies/ml) followed by VL
re-suppression (Jobanputra et al., 2015). Although the results from
these studies are not directly comparable to the present study
findings, they show that detectable viraemia is common in
paediatric patients. A multicentre cohort study of data on children
with HIV in the UK and Ireland showed that 22% of participants
with sustained viral suppression experienced transient viraemia
(defined as a single VL >50 copies/ml between two VL tests below
50 copies/ml), with an incidence of 12 per 100 person-years,
similar to the findings in our study (Lee et al., 2007).
The incidence of LLV and VF after reaching VL suppression was
also significantly higher in children than in adults. Furthermore, in
the present study, adolescents (those aged 10 years) were more
likely to experience VF compared to younger children, a finding
that has also been reported by other studies conducted in Africa
(Makadzange et al., 2015). Adolescence is a period of particularly
high risk for poor adherence (Mukui et al., 2016; Nachega et al.,
2009). Taken together, these emphasize the need for investigating
and addressing factors that impede viral suppression among
adolescents.The rate of VF in children who reached VL suppression is lower
than those reported by other studies (Makadzange et al., 2015;
Salou et al., 2016). A possible reason for the higher VF rates
reported in other studies is the cross-sectional design of studies
and lack of information regarding initial VL suppression prior to
inclusion in the study (Fokam et al., 2017; Salou et al., 2016). Due to
regular VL monitoring and the longitudinal design of our study, it
was possible to distinguish between those who developed VF and
those who never reached suppression. Another explanation for low
VF in our cohort is the high standard of care provided at Newlands
Clinic, with routine VL testing, continuous adherence monitoring
support, and a rapid response with intensified adherence
counselling and/or ART switch among those who have a non-
suppressed VL (Haas et al., 2015). Routine VL testing, which is not
available as standard of care in many low-income settings, can
detect VF earlier than targeted VL monitoring, i.e., VL testing
prompted by clinical or immunological deterioration.
A number of studies have shown that episodes of LLV and viral
blips are associated with an increased risk of subsequent VF in
adults (Antiretroviral Therapy Cohort C et al., 2015; Grennan et al.,
2012; Laprise et al., 2013; Leierer et al., 2016). While some studies
have suggested that episodes of transient viraemia may result in
the selection of drug-resistant HIV strains, leading to an increased
risk of VF (Clutter et al., 2016; Gonzalez-Serna et al., 2014; Swenson
et al., 2014b), others have found no link between blips and HIV
progression (Havlir et al., 2001; Kanapathipillai et al., 2014; Nettles
et al., 2005). Young et al. found a gradual increase in the risk of VF
with increasing blip magnitude (Young et al., 2015). In another
study, only blips of 500–999 copies/ml magnitude were associated
with the increased risk of viral rebound (Grennan et al., 2012). In
contrast, other studies have shown no evidence of an association
between blips and VF in adults (Kanapathipillai et al., 2014;
Martinez et al., 2005; Sklar et al., 2002). However, these studies
have been conducted largely in adults. In the present study, not
only did children have a higher risk of VF, but they also had a higher
incidence of viral blips as well as LLV, and the significance of these
in predicting VF needs further study. Furthermore, careful
virological monitoring is warranted in children.
The strengths of this study are the use of a standardized
definition for viral blips, regular VL monitoring, availability of
detailed clinical data including adherence data, and good follow-
up rates. The limitations of the study include the relatively small
sample size and low number of blips in each age group, and there
may therefore be inadequate power to detect an association
between the covariates and the incidence of viral blips. Further-
more, the follow-up period was not long enough to investigate
whether blips or LLV increase the risk of subsequent VF. Adherence
may have been over-estimated, as the pill count is not the optimal
measure of adherence.
In conclusion, this study demonstrated that detectable viraemia
is common among children, although its role with regard to long-
term outcomes necessitates further study in low-income settings,
especially where HIV prevalence is high and the availability of VL
monitoring remains limited.
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share the work provObjective: HIV disrupts host defense mechanisms and maintains chronic inflammation
in the lung. Nitric oxide is a marker of lung inflammation and can be measured in the
exhaled air. We investigated the relationship between exhaled nitric oxide (eNO), HIV
status and airway abnormalities in perinatally HIV-infected children aged 6–19 years.
Design: A cross-sectional study.
Methods: HIV-infected individuals on antiretroviral therapy and HIV-uninfected chil-
dren with no active tuberculosis (TB) or acute respiratory tract infection were recruited
from a public hospital in Harare, Zimbabwe. Clinical history was collected and
eNO testing and spirometry was performed. The association between eNO and
explanatory variables (HIV, FEV1 z-score, CD4þ cell count, viral load, history of
TB) was investigated using linear regression analysis adjusted for age, sex and time
of eNO testing.
Results: In total, 222 HIV-infected and 97 HIV-uninfected participants were included.
Among HIV-infected participants, 57 (25.7%) had a history of past TB; 56 (25.2%) had
airway obstruction, but no prior TB. HIV status was associated with lower eNO level
[mean ratio 0.79 (95% confidence interval, 95% CI 0.65–0.97), P¼0.03]. Within the
HIV-infected group, history of past TB was associated with lower eNO levels after
controlling for age, sex and time of eNO testing [0.79 (95% CI 0.67–0.94), P¼0.007].
Conclusion: HIV infection and history of TB were associated with lower eNO levels.
eNO levels may be a marker of HIV and TB-induced alteration in pulmonary physiol-
ogy; further studies focused on potential causes for lower eNO levels in HIV and TB are
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Access to antiretroviral therapy (ART) has substantially
increased survival of children with HIV, with increasing
numbers now reaching adolescence and adulthood.
However, it is becoming increasingly apparent that
HIV infection is associated with chronic comorbidities in
the ART era [1,2].
In recent years, several studies from sub-Saharan Africa
have shown that chronic respiratory symptoms and airway
obstruction are common among children taking ART [3–
6], with obliterative bronchiolitis and bronchiectasis being
common noncommunicable causes of chronic respiratory
symptoms [7–12]. Furthermore, ART is not fully
protective against tuberculosis (TB) and individuals with
HIV on ART have an estimated 10% four-year risk of
developing TB compared with a 10% lifetime risk in the
general population of South Africa [13,14]. Moreover,
children with HIVexperience more rapid TB progression,
poorer response to treatment and are at a higher risk of TB
recurrence [15,16]. The long-term consequences of TB
often persist despite successful treatment, adding to the
burden of chronic lung disease [17].
Even though the pathogenesis of chronic lung disease in
HIV-infected individuals is not completely understood,
chronic airway inflammation and oxidative stress are
thought to play a distinct role [12,18]. One of the markers
of airway inflammation is nitric oxide that is produced by
various cells in the body, including the respiratory tract.
Under normal physiological conditions, there is constant
production of NO in the lung that regulates broncho-
dilation, neurotransmission, mucous secretion and the
inflammatory response [19,20]. The presence of NO can
be easily measured in exhaled air using a noninvasive,
quantitative, standardized method [21]. Increased levels of
exhaled nitric oxide (eNO) are a well known marker of
eosinophilic airway inflammation in asthma, while
reduced eNO levels have been reported in patients with
active lung TB, cystic fibrosis and in smokers [22–24].
Increased eNO levels are explained by overexpression of
the inducible NO synthase (iNOS), which often
correlates with systemic and lung inflammation, while
decreased eNO levels may be due to lack of the substrate
(L-arginine); reduced activity of iNOS in the airways
(which may be directly inhibited as an immune evasion
mechanism by Mycobacterium tuberculosis) or thick mucus
that may inhibit the NO diffusion into exhaled air (e.g. in
cystic fibrosis) [25–27].
Current data suggest that eNO may be a useful tool to
guide asthma management in both children and adults
[28,29], though its clinical application for other lung
disorders is unclear. A recent study showed that increased
eNO levels may predict clinical response to inhaled
corticosteroids in adults with nonspecific respiratory
symptoms [30].Data investigating the association between HIV infection
and eNO levels are scarce [31]. Although lower levels of
eNO were found in one study among 36 HIV-infected
patients [31] compared with HIV-uninfected healthcare
workers, no significant difference in eNO levels were
reported in patients with HIV-TB coinfection compared
with HIV-uninfected patients with TB [22,32]. No
studies so far have investigated the level of eNO in
children with HIV-associated chronic lung disease.
In this study, we aimed to compare the levels of eNO in
children with and without HIV and investigated the
association between eNO and history of TB and airway
obstruction in HIV-infected children on ART.Materials and methods
Study population
This cross-sectional study was conducted between April
2017 and August 2018 as a substudy of a randomized
controlled clinical trial investigating the effect of
azithromycin in children with HIV-associated chronic
lung disease (BREATHE trial, clinicaltrials.gov identifier
NCT02426112). The detailed study protocol has been
published elsewhere [33]. Participants were eligible for
the trial if they were aged 6–19 years, had perinatally
acquired HIV and had been taking ART for at least 6
months, and had no evidence of active TB or acute
respiratory tract infection. The trial is being conducted in
Malawi and Zimbabwe, but the substudy was conducted
in Zimbabwe only at the Harare Central hospital
paediatric HIV clinic, the largest public sector HIV
clinic in Harare.
TB may cause lung tissue changes (bronchovascular
distortion, fibrotic lesions and cavitation) persisting
beyond the acute episode [17]; these morphological
changes may influence eNO levels. We expected to find a
high prevalence of past TB because of the high incidence
of TB in people living with HIV. Thus, we divided HIV-
infected participants into three groups on the basis of
clinical history and spirometry results: normal lung
function and no TB history; history of TB irrespective of
airway obstruction; and airway obstruction and no TB
history. Airway obstruction was defined as forced
expiratory volume in 1 s (FEV1) z-score less than -1.64
with no reversibility (<12% improvement in FEV1 after
salbutamol 200 mg inhaled using a spacer).
In addition, a group of HIV-uninfected participants was
recruited from the same catchment area as the HIV-
infected group. HIV-uninfected children (were tested for
HIVat enrolment) aged 6–16 years with no prior history
of heart/lung diseases (including history of TB), no
reported chest pain after exercise, shortness of breath
Levels of exhaled nitric oxide in HIV infection Sovershaeva et al. 1713during exercise or chronic cough and normal lung
function were eligible for the study as a control group.
Ethical approval
The study was approved by the London School of Hygiene
and Tropical Medicine Ethics Committee; the Harare
Central Hospital Ethics Committee; the Medical Research
Council of Zimbabwe; Regional Committee for Medical
and Health Research Ethics in Norway (2015/1650).
Written informed consent by guardian and assent by
participants aged less than 18 years were obtained. Those
aged 18 years and older gave independent consent.
Study procedures
A detailed questionnaire regarding demographic and
clinical history was administered to all participants.
Participants were explicitly asked about current and
previous respiratory symptoms (chronic cough, wheezing
and dyspnoea) in the past 3 months. Self-reported and/or
physician-diagnosed lung diseases and/or atopic disorders
including rhinitis and atopic dermatitis were recorded.
Participants were classified as having asthma based on
clinical history of diagnosed asthma or self-reported
symptoms of asthma (episodes of wheezing, nocturnal
tightness in the chest, attacks of shortness of breath
following strenuous activity, at rest or at night-time) or
treatment with asthma-specific medications (short-term/
long-term b2 agonists; inhaled corticosteroids; leukotri-
ene receptor antagonists; methylxanthines).
Measurement of exhaled nitric oxide
The level of eNO was measured by the electrochemical
analyser (NIOX VERO, Circassia, UK) according to
American Thoracic Society (ATS) guidelines [21] and
expressed in parts per billion (ppb). The calibration of the
machine and quality control were performed according to
the manufacturer’s instructions. The participants were
asked to sit and rest for a minimum of 5 min before the
measurement. Repeated exhalations were performed in
order to obtain at least two measurements that agreed
within 10%. Measurements were taken with a minimum
of 30 s rest time in between. Up to six eNO measurement
attempts were made and the mean eNO value was
calculated from two eNO measurements with minimal
difference between them. All eNO measurements were
performed between 0800 and 1400 h and exact time of
the testing was recorded.
Spirometry
Spirometry was performed after eNO measurement using
EasyOne spirometer (ndd Medical Technologies Inc.,
Andover, Massachusetts, USA) according to the ATS
guidelines. FEV1 z-scores were calculated using prediction
equations from the Global Lung Function Initiative [34].
Laboratory tests
All participants provided blood samples for full blood
count, and for participants with HIV, also for HIVviral load and CD4þ cell count testing. HIV viral load
was measured using the Gene Xpert assay, with a limit
of detection of 40 copies/ml (XpertTM HIV-1 Viral
Load; Cepheid, Sunnyvale, California, USA) and
CD4þ cell count was measured as a point of care test
using a PimaTM Analyser (Alere, Orlando, Florida,
USA). Anaemia was defined according to WHO
criteria (haemoglobin <11.5 g/dl for children 6–11.9
years; haemoglobin <12 g/dl for children 12–14.9 years;
haemoglobin <12 g/dl for girls aged 15 years; haemo-
globin <13 g/dl for boys aged 15 years) [35].
Data collection
Electronic record forms (for questionnaires) collected on
Google Nexus tablets (Google, Mountain View, Cali-
fornia, USA) with OpenDataKit software and paper
forms (for clinical tests) were used for data collection.
Data from paper forms were extracted using CARDIFF
TELEFORM character optical mark recognition soft-
ware (Version 10.9). Data were stored in Microsoft Access
database (Microsoft, Redmond, Washington, USA).
Statistical analysis
All statistical analyses were performed using STATA
Version 14 (StataCorp LLC, College Station, Texas,
USA). Values for eNO were presented as geometric mean
with 95% confidence interval. Weight-for age and
height-for-age z-scores were calculated using British
1990 Growth Reference Curves [36], with z-scores less
than -2 representing wasting and stunting, respectively.
Characteristics between study groups were compared
using Fisher’s exact test (for categorical parameters) and
Kruskal–Wallis or Wilcoxon rank sum test (for continu-
ous parameters). The values of eNO were not normally
distributed and therefore were log transformed to
approximate normality. The analyses were performed
with log-transformed eNO data and back transformed to
present geometric mean. The association between eNO
levels and a priori defined explanatory variables was
studied using linear regression analysis. Explanatory
variables included HIV status, age, sex, anthropometric
parameters, haemoglobin level, haematocrit, white blood
cell count, neutrophil count, eosinophil count, FEV1 z
score, atopic status, passive smoking, for all participants;
CD4þ cell count, viral load, history of TB and presence of
airway obstruction, for participants with HIV only. Age,
sex and exact time of eNO testing were adjusted for a
priori. Parameters were included into multivariable linear
regression model if they showed a significant effect on the
prediction of eNO level in age, sex and time of eNO
testing adjusted models at P value less than 0.05.
Adjustment for unbalanced parameters (for HIV-infected
group) was also performed. Variance inflation factor was
used to detect multicollinearity in the multivariable
models. Height was not included into multivariable
regression models due to high collinearity with age. The
linear association between eNO and continuous variables
1714 AIDS 2019, Vol 33 No 11was estimated graphically. Residual analysis with residual
plots and normal probability plots of residuals confirmed
no violation of the linear regression assumptions.Results
In total, 227 HIV-infected and 104 HIV-uninfected
children were enrolled. Five participants (n¼ 1 HIV-
infected, n¼ 4 HIV-uninfected) aged 6–7 years did not
understand the procedure and were excluded from the
study. Of the remaining participants, acceptable eNO
measurements were obtained from 225 HIV-infected and
98 HIV-uninfected children. A total of four participants
were excluded from the study for the following reasons:
abnormal spirometry (n¼ 1, HIV-uninfected) and miss-
ing spirometry data (n¼ 3, HIV-infected).
Baseline characteristics of study participants and their
distribution across the four groups are presented in Table
1. The median time on ART among HIV-infected
children was 6.6 years (IQR 4.0–8.4) and comparable
across the three different groups. HIV-infected children
overall were more likely to be wasted and stunted
compared with HIV-uninfected children (wasted: 41.9
vs. 3.1%, P< 0.001; stunted: 42.8 vs. 4.1%, P< 0.001).
Anaemia was more common in HIV-infected than HIV-
uninfected children (31.2 vs. 9.3%, P< 0.001). Exposure
to passive smoking was more common in HIV-infected




Age (years), Median (IQR) 15 (12–18)
Female sex, N (%) 26 (45.6)
Wasting (weight for age z-score<2), N (%) 30 (52.6)
Stunted (height-for-age z-score<2), N (%) 26 (45.6)
Passive smoking, N (%) 21 (36.8)
Living in high-density area, N (%) 53 (94.6)
eNO level (ppb), geometric mean (95% CI) 13.7 (12.2–15.5)
FEV1 z-score, Median (IQR) 1.8 (2.3 to 1.3)
Presence of atopy (asthma, eczema,
allergic rhinitis), N (%)
12 (21.0)
Haemoglobin (g/dl), Median (IQR) 13 (11.9–13.7)
Haematocrit, %, Median (IQR) 36.7 (34.0–38.4)
White blood cell count (M109/l), Median (IQR) 4.3 (3.8–5.4)
Eosinophil count (M109/l), Median (IQR) 0.075 (0.04–0.12)
Neutrophil count (M109/l), Median (IQR) 1.7 (1.3–2.2)
Lymphocyte count (M109/l), Median (IQR) 2.0 (1.6–2.6)
Monocyte count (M109/l), Median (IQR) 0.39 (0.32–0.48)
Anaemia, N (%) 15 (26.8)
Viral load (log10 copies/ml), Median (IQR) 2.7 (1.6–4.0)
CD4þ cell count (cells/ml), Median (IQR) 509 (339–702)
Years on ART, Median (IQR) 6.8 (4.6–9.1)
PI-based regimen, N (%) 25 (43.9)
ART, antiretroviral therapy; IQR, interquartile range; eNO, exhaled nitricAmong HIV-infected participants, those with a history of
prior TB had significantly higher prevalence of wasting
than participants with no airway abnormalities (52.6 vs.
28.4%, P¼ 0.001, respectively). In addition, participants
with a history of prior TB received a protease inhibitor
based regimen more often than other two groups. The
prevalence of both stunting and wasting was higher in
participants with airway obstruction when compared
with those with no airway abnormalities (stunted: 58.9 vs.
33.0%, P< 0.001; wasted: 57.1 vs. 28.4%, P< 0.001).
HIV status was associated with lower eNO levels after
adjusting for age, sex and time of eNO testing [geometric
mean ratio 0.79 (95% CI 0.65–0.97), P¼ 0.03]. Among
HIV-infected participants, those with a history of TB had
significantly lower eNO levels than those without TB
whether they had airway obstruction [geometric mean
13.7 (95% CI 12.2–15.5) vs. 16.9 (95% CI 14.3–19.8),
P¼ 0.03] or had no airway abnormalities [geometric
mean 17.9 (95% CI 16.0–20.0), P¼ 0.003] (Fig. 1).
Linear regression analysis controlled for age, sex and time
of eNO testing confirmed the association between past
TB and lower eNO levels (Table 2).
The association between participant characteristics and
eNO levels in HIV-infected and HIV-uninfected
participants are presented in Tables 2 and 3, respectively.
The level of eNO increased with increasing age and
height in HIV-infected children. Higher haemoglobin
level and neutrophil count were associated with higher
eNO level in adjusted analysis. Female sex was associatedHIV-infected
Airway obstruction,







15 (13–18) 16 (12–18) 10 (7–12)
18 (32.1) 71 (65.1) 47 (48.4)
32 (57.1) 31 (28.4) 3 (3.1)
33 (58.9) 36 (33.0) 4 (4.1)
15 (26.8) 25 (22.9) 3 (3.1)
49 (96.1) 100 (93.5) 95 (97.9)
16.9 (14.3–19.8) 17.9 (16.0–20.0) 16.5 (14.8–18.5)
2.1 (2.7 to 1.9) 1.1 (1.3 to 0.4) 0.2 (0.6 to 0.3)
12 (21.4) 13 (11.9) 10 (10.3)
12.7 (11.6–13.6) 12.8 (11.7–14) 13.2 (12.4–13.9)
35.2 (33.3–37.9) 36 (33.4–38.6) 36.3 (34.8–39)
4.6 (3.3–5.3) 4.2 (3.6–5) 5.3 (4.5–6.3)
0.065 (0.02–0.13) 0.06 (0.03–0.16) 0.1 (0.06–0.2)
1.7 (1.1–2.5) 1.8 (1.4–2.4) 2.2 (1.8–2.9)
2.1 (1.6–2.7) 2.0 (1.6–2.3) 2.3 (2.0–2.8)
0.39 (0.30–0.5) 0.35 (0.27–0.46) 0.47 (0.36–0.63)
17 (32.7) 35 (32.7) 9 (9.3)
2.5 (1.6–3.7) 2.1 (1.6–3.4) –
559 (326–728) 624 (355–779) –
5.9 (3.6–7.8) 6.5 (4.0–8.4) –
12 (21.4) 12 (11.0) –
oxide; FEV1, forced expiratory volume in 1 s; PI, protease inhibitor.
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Fig. 1. Level of exhaled nitric oxide in HIV-infected and HIV-
uninfected participants. Horizontal lines indicate geometric
mean values.with lower eNO level in adjusted analysis. Due to
imbalances in wasting, stunting and use of protease
inhibitor based regimen by HIV-infected groups, these
variables were adjusted for in multivariable analysis. On
multivariable linear regression, haemoglobin, neutrophil
count, history of TB and age remained significantly
associated with eNO levels in HIV-infected participants.Table 2. Analysis of factors associated with exhaled nitric oxide level in
Unadjusted
analysis
Variables GMRa (95% CI) P
Age (years) 1.03 (1.00–1.05) 0.0
Female sex 0.89 (0.77–1.03) 0.1
Weight (kg) 1.01 (1.00–1.01) 0.0
Height (cm) 1.01 (1.00–1.02) <0.0
Weight-for-age z-score 1.01 (0.96–1–06) 0.7
Height-for-age z-score 1.06 (1.00–1.13) 0.0
Wasting (weight for age z-score<2) 0.97 (0.83–1.13) 0.6
Stunted (height-for-age z-score<2) 0.93 (0.80–1.08) 0.3
Passive smoking (ref. no) 1.19 (1.00–1.40) 0.0
History of tuberculosis 0.78 (0.67–0.90) 0.0
FEV1 z-score 1.01 (0.95–1.07) 0.7
FEV1 z-score<1.64 (airway obstruction) 0.92 (0.79–1.08) 0.3
Presence of atopy 0.94 (0.77–1.15) 0.5
Haemoglobin (g/dl2 ) 1.07 (1.03–1.12) 0.0
Haematocrit, % 1.02 (1.00–1.03) 0.0
White blood cell count (log transformed) 1.17 (0.92–1.49) 0.2
Eosinophil count (log transformed) 1.03 (0.97–1.10) 0.3
Neutrophil count (log transformed) 1.19 (1.05–1.35) 0.0
Lymphocyte count (log transformed) 0.91 (0.78–1.08) 0.2
Monocyte count (log transformed) 1.16 (0.96–1.40) 0.1
Anaemia (ref. no) 0.97 (0.82–1.14) 0.7
HIV viral load (log10 copies/ml) 1.00 (0.95–1.05) 0.9
CD4þ cell count (cells/ml) 1.00 (0.99–1.00) 0.0
Years on ART 0.99 (0.97–1.02) 0.7
PI-based regimen (NNRTI-based as ref.) 0.85 (0.71–1.02) 0.0
ART, antiretroviral therapy; CI, confidence interval; eNO, exhaled nitric o
aGeometric mean ratio.In HIV-uninfected individuals, anthropometric param-
eters (height and weight) were significantly positively
associated with eNO level in univariate analysis, though
the association became nonsignificant after accounting for
age, sex and time of eNO testing. Higher haemoglobin
level and haematocrit were associated with higher eNO
level, while wasting was associated with lower eNO level
in univariate and adjusted analysis. On multivariable
analysis, wasting, haemoglobin and age remained
significantly associated with eNO levels in HIV-
uninfected participants.Discussion
Our study showed that children with HIV infection have
lower eNO levels than HIV-uninfected children. HIV-
infected children with a prior historyof TB had significantly
lower eNO levels than those without prior TB.
There are few data on the levels of eNO in HIV-infected
adults [31], and none among children. Two studies
reported lower eNO levels associated with HIV infection
among adults with [32] and without TB [31], mirroring
the results of our study. However, a study including 19
HIV-infected and 126 HIV-uninfected adults with TB
did not find any difference in eNO, but was likely
underpowered [22]. The observed low eNO levels inHIV-infected participants.




GMRa (95% CI) P GMRa (95% CI) P
04 1.03 (1.01–1.05) 0.003 1.03 (1.01–1.05) 0.005
3 0.85 (0.74–0.99) 0.04 0.86 (0.74–1.01) 0.07
02 1.01 (1.00–1.02) 0.16
01 1.02 (1.01–1.03) <0.001
2 1.00 (0.94–1.05) 0.94
7 1.05 (0.99–1.13) 0.12
8 0.99 (0.85–1.16) 0.95 1.01 (0.84–1.22) 0.89
3 0.94 (0.81–1.09) 0.41 0.94 (0.80–1.12) 0.51
4 1.17 (0.99–1.38) 0.06
04 0.79 (0.67–0.94) 0.007 0.80 (0.68–0.95) 0.013
3 0.98 (0.92–1.05) 0.59
3 0.92 (0.78–1.09) 0.33
4 0.94 (0.77–1.15) 0.55
02 1.06 (1.01–1.11) 0.009 1.07 (1.02–1.12) 0.004
23 1.01 (1.00–1.02) 0.12
0 1.57 (0.90–2.71) 0.11
3 1.04 (0.97–1.11) 0.26
12 1.46 (1.07–1.99) 0.016 1.19 (1.05–1.36) 0.008
8 0.96 (0.66–1.41) 0.84
2 1.36 (0.89–2.08) 0.15
1 0.97 (0.83–1.15) 0.75
5 0.99 (0.95–1.05) 0.86
7 1.00 (0.99–1.01) 0.34
0 0.98 (0.95–1.00) 0.13
9 0.86 (0.72–1.03) 0.11 0.90 (0.75–1.08) 0.27
xide; FEV1, forced expiratory volume in 1 s; PI, protease inhibitor.
1716 AIDS 2019, Vol 33 No 11
Table 3. Analysis of factors associated with exhaled nitric oxide level in HIV-uninfected participants.
]Unadjusted
analysis




Variables GMRa (95% CI) P GMRa (95% CI) P GMRa (95% CI) P
Age 1.09 (1.05–1.13) <0.001 1.08 (1.05–1.12) <0.001 1.07 (1.03–1.11) 0.001
Female sex 1.25 (1.01–1.56) 0.04 1.14 (0.93–1.40) 0.21 1.14 (0.92–1.41) 0.22
Weight (kg) 1.02 (1.01–1.03) <0.001 1.01 (0.99–1.03) 0.42
Height (cm) 1.02 (1.00–1.02) <0.001 1.01 (0.99–1.03) 0.15
Weight-for-age z-score 1.00 (0.88–1.13) 0.99 1.00 (0.88–1.13) 0.99
Height-for-age z-score 1.04 (0.93–1.16) 0.50 1.04 (0.93–1.17) 0.50
Wasting (weight for age z-score<2) 0.45 (0.24–0.85) 0.014 0.45 (0.24–0.85) 0.015 0.52 (0.29–0.92) 0.03
Stunted (height-for-age z-score<2) 0.70 (0.40–1.22) 0.21 0.70 (0.40–1.23) 0.21
Passive smoking (ref. no) 1.52 (0.80–2.88) 0.20 1.12 (0.61–2.04) 0.71
FEV1 z-score 1.01 (0.87–1.18) 0.87 1.01 (0.86–1.18) 0.90
Presence of atopy 1.08 (0.75–1.56) 0.67 1.05 (0.75–1.47) 0.75
Haemoglobin (g/dl2) 1.13 (1.05–1.23) 0.003 1.09 (1.01–1.19) 0.031 1.09 (1.00–1.18) 0.04
Haematocrit, % 1.07 (1.04–1.11) <0.001 1.05 (1.01–1.08) 0.009
White blood cell count (log transformed) 0.89 (0.66–1.20) 0.45 0.94 (0.49–1.81) 0.86
Eosinophil count (log transformed) 1.03 (0.92–1.14) 0.62 1.05 (0.95–1.16) 0.32
Neutrophil count (log transformed) 0.97 (0.78–1.20) 0.76 1.06 (0.66–1.71) 0.79
Lymphocyte count (log transformed) 0.94 (0.64–1.37) 0.74 1.04 (0.45–2.40) 0.92
Monocyte count (log transformed) 0.81 (0.62–1.05) 0.12 0.78 (0.44–1.40) 0.41
Anaemia (ref. no) 1.13 (0.77–1.66) 0.52 1.13 (0.77–1.67) 0.53
CI, confidence interval; eNO, exhaled nitric oxide; FEV1, forced expiratory volume in 1 s.
aGeometric mean ratio.HIV-infected children may be explained by immunolog-
ical and pathophysiological mechanisms. Alveolar macro-
phages play a central role in the defense against bacterial
and mycobacterial infection; they may become infected
with HIVand constitute the primary reservoir of the virus
in the lung [37,38]. During HIV infection, alveolar
macrophage function is compromised [37], with evidence
of oxidative stress [39] and reduced ability to phagocytose
and kill bacteria [40,41]. HIV-associated chronic activa-
tion of inflammatory cells in the alveolar space may
further compromise the host response against infectious
stimuli [42,43]. Thus, low levels of eNO detected in
patients with HIV may reflect the inability of alveolar
macrophages to produce eNO as part of the lung innate
immune system. This may contribute to persistent lung
immune dysfunction.
eNO levels are known to increase with age. This needs to
be taken into consideration when interpreting eNO levels
measured in children. Values of eNO increase linearly
between 6 and 16 years in parallel with the somatic
growth [44]. The ATS guidelines recommend adjustment
for age when interpreting the eNO levels in children
younger than 12 years of age [45]. In addition, the
majority of published studies have reported an association
between height and eNO levels [46–49]. Total airway
mucosal surface area for NO diffusion increases with
increasing age and height, thus leading to higher eNO
levels [50]. In our study, both age and height were
significantly associated with eNO levels in HIV-infected
children. Given that HIV-infected children are generally
smaller than their HIV-uninfected peers, this might partly
explain the lower eNO levels among HIV-infected
children observed in our study.An interesting finding of our study was that history of TB
in HIV-infected participants was associated with lower
eNO levels. No studies have investigated the level of
eNO in individuals with a history of TB, though a
number of studies were conducted in adult patients with
active lung TB [22,32,51]. At least two studies found that
eNO levels were lower in patients with newly diagnosed
untreated lung TB than healthy controls [22,32].
Moreover, one of these studies reported an association
between low eNO levels at the time of TB diagnosis and
severity of disease [22].
M. tuberculosis (Mtb) may persist in alveolar macrophages for
a prolonged period of time [52,53]. Nonreplicating
persistence of Mtb may maintain chronic airway inflam-
mation and may lead to lung fibrosis [17]. There is some
evidence from in-vitro studies that nitric oxide has a
protective role in the progression of lung fibrosis [54].
Thus, lower levels of eNO in patients treated for TB in our
study may reflect altered lung immune response mediating
the development of chronic lung complications.
No association was found between airway obstruction
measured as FEV1 z score less than -1.64 and eNO levels
in HIV-infected children. This is in line with several other
studies reporting no association between FEV1 and eNO
in adults with chronic obstructive lung disease [55,56],
implying that eNO has probably no pathophysiological
role in the obstruction, but rather a marker of the
underlying condition, as seen in eosinophilic inflamma-
tion in asthma patients [57].
In our study, we found significant positive associations
between several blood parameters and eNO levels. The
Levels of exhaled nitric oxide in HIV infection Sovershaeva et al. 1717associations between haemoglobin level, haemotocrit and
eNO may reflect physiological processes at the level of
endothelium. Increased haematocrit results in increased
shear stress and production of NO. The positive
association between eNO and blood neutrophils
observed in HIV-infected participants may be explained
by the fact that neutrophils can produce nitric oxide in
response to foreign stimuli [58]. However, in cystic
fibrosis patients, an inverse correlation between blood
neutrophils and eNO levels was reported, which was
thought to be due to the ability of neutrophils to produce
superoxide that downregulates nitric oxide production
[24]. The observed associations emphasize the need to
interpret eNO results with caution. eNO levels are
influenced by a multitude of factors, including demo-
graphic, anthropometric and biological factors, thus
questioning the utility of eNO as a clinical tool in
conditions beyond asthma. Although noninvasive nature
and measurement simplicity make eNO testing an
attractive tool for resource-limited settings, it is too early
to forecast its applicability and clinical usefulness among
HIV-infected children with airway abnormalities in a
given setting.
The strengths of the study are its prospective design,
relatively large sample size, use of standardized protocol
for eNO testing and spirometry performed by well
trained nurses. Study limitations include self-report of TB
with no information regarding TB localization (pulmo-
nary or extrapulmonary), raising concerns of recall bias.
Among other determinants that may have an impact on
eNO levels and that were not assessed in the present study
are genetic factors (affecting the activity of nitric oxide
synthase), environmental factors (air pollution) and
socioeconomic factors.
In summary, our study shows that both HIV infection and
history of TB are associated with lower eNO levels, with
no association found between eNO and airway obstruc-
tion. The low eNO levels may be a marker of abnormal
pulmonary physiology due to perinatally acquired HIV
infection and post-TB lung changes. The role of nitric
oxide in the pathogenesis of HIV infection needs
further investigation.Acknowledgements
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Background: HIV infection causes impairment of the gastrointestinal barrier, with 
substantial depletion of CD4+ T-cells in the gut. Antiretroviral therapy (ART) restores 
the CD4+ counts and may have beneficial effects on gut microbiota in adults. Little is 
known about effect of long-term ART on gut microbiome in HIV infected children. We 
investigated composition of gut microbiota in HIV infected and uninfected children and 
assessed associations between gut microbiota and patient characteristics. 
Methods: A cross-sectional study. Rectal swabs were collected from 177 HIV infected 
and 103 HIV uninfected controls. Gut microbial composition was explored using 16S 
rRNA sequencing (Illumina Miseq).  
Results: HIV infected children had significantly lower alpha-diversity and higher beta-
diversity compared to HIV uninfected. No association was observed between 
microbiome diversity and CD4+ T-cell counts, HIV viral load or HIV-associated CLD. 
We found enriched levels of Corynebacterium (p<0.01), Finegoldia (p<0.01) and 
Anaerococcus (p<0,01) in HIV infected, and enrichment of Enterobacteriaceae 
(p=0.02) in participants with low CD4+ counts (<400 cells/mm3). Prolonged ART-
treatment (³10 years) was significantly associated with a richer gut microbiota by alpha 
diversity. 
Conclusion: HIV infected children have altered gut microbiota. Our results suggest that 
prolonged ART minimize the differences in gut microbiota between HIV infected and 
uninfected participants. 
 































The gastrointestinal (GI) tract plays an important role in the pathogenesis of human 
immunodeficiency virus (HIV) infection, with the majority of CD4+ T-cells residing in 
the GI-tract and associated lymphatic tissue [1]. HIV-induced depletion of CD4+ T-cells 
causes structural impairment of the GI epithelial barrier, systemic microbial 
translocation and ultimately alteration of the gut microbial community composition [2]. 
 
Recent evidence indicates that HIV-associated gut dysbiosis is characterized by 
decreased abundance of commensal (protective) bacteria and an enrichment of potentially 
pathogenic taxa [3]. For example, the genera Pseudomonas, Enterobacteriaceae, 
Acinetobacter and Campylobacter are thought to have infectious and inflammatory 
properties and are significantly enriched in adults with HIV [3, 4].  
 
Studies show that altered gut microbiota is associated with elevated inflammatory 
markers such as C-reactive protein and interleukin-6 [5-8] as well as with markers of 
microbial translocation such as lipopolysaccharide and lipopolysaccharide binding 
protein [9, 10]. Dinh et al. found a positive correlation between relative abundance of 
Enterobacteriaceae and markers of chronic inflammation in HIV infected, antiretroviral 
(ART)-treated individuals with undetectable plasma HIV RNA [11]. Further, studies 
suggest that ART may only partially restore the gut microbiota towards levels observed 
in HIV uninfected population, and patients continue to suffer from dysbiosis even when 
HIV infection is controlled [1, 12, 13].  
 
Moreover, gut dysbiosis may be associated with the development of chronic non-
infectious HIV complications, such as cardiovascular disease and lung complications [14, 
15]. Systemic chronic inflammation due to gut microbial translocation and gut dysbiosis 
may have some relation to the development of chronic complications [16, 17]. 
 
So far, no studies have investigated the gut microbiome in children in sub-Saharan Africa 
and its relation to the development of HIV-associated chronic complications. The overall 
aim of our study was to investigate the gut microbiota in HIV infected and HIV uninfected 
children in Harare (Zimbabwe), and to evaluate the association between gut microbial 
composition and clinical and laboratory parameters (CD4+ T-cell count, viral load).  
 
Materials and methods 
Study population 
This study investigated bacterial profiles of rectal swabs collected from participants of 
the Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic 
Lung Disease in HIV-infected Children (BREATHE) trial [18] (clinicaltrials.gov 
identifier NCT02426112). CLD was defined as forced expiratory volume in one second 
(FEV1) z-score less than -1.0 with no reversibility (<12% improvement in FEV1 after 200 
ug of salbutamol inhaled using a spacer). The detailed study protocol has been described 
previously [18]. For the present sub study only participants enrolled in Harare 
(Zimbabwe) were included. In addition, HIV uninfected children aged 6-16 years from 
the same area with no prior history of heart/lung diseases, tuberculosis (TB), no chronic 
cough, reported chest pain or shortness of breath during exercise were recruited for the 
control group. All study participants completed a detailed questionnaire regarding 
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Rectal swabs were collected from all participants at enrolment into the trial by study 
nurses. Swabs were immediately preserved in 1,5 ml of transport medium PrimeStore ® 
MTM (Longhorn diagnostics, Maryland, USA) and directly stored on ice for a maximum 
of one hour, and then frozen at -80 °C before shipment on dry ice to the laboratory at 




The Zymo Research Quick-DNATM Fecal/Soil Microbe Microprep kit (Zymo Research, 
California, USA) was used for DNA extractions. DNA was extracted according to the 
manufacturer’s description, with modifications. Briefly, an aliquot of 400 µl of each 
sample was mixed with 400 µl of BashingBeadTM Buffer in a ZR BashingBeadTM Lysis 
Tube. Mechanical lysis (bead beating) was performed using the TissueLyser LTTM 
(QIAGEN, Hilden, Germany) set to 50 Hz for 5 minutes. Then 500 µl of supernatant was 
transferred to a Zymo-SpinTM III-F Filter (Zymo Research, California, USA) and 
centrifuged at 8000 x g for 1 minute. Further chemical lysis was done by adding Genomic 
Lysis Buffer. All other procedures were done according to the manufacturers protocol.  
 
16S library preparation and gene sequencing 
In order to assess DNA quality and the total bacterial load extracted, a real-time 
quantitative polymerase chain reaction (qPCR) was performed as previously described 
[19]. Subsequently, two sets of PCRs targeting the V4 hypervariable region of the 16S 
ribosomal ribonucleic acid (rRNA) gene using the primers 515F and 806R were 
performed according to previously described protocols [20, 21]. For details on laboratory 
procedure see Supplementary file 1. 
 
Samples were sequenced on an Illumina Miseq® instrument using the Miseq® Reagent 
v3 kit, (600 cycles) (Illumina, California, USA). The final library was diluted to a 6 pM 
concentration, and a 25% PhiX library spike-in was added at 6 pM as internal control 
[22]. The pre-processing of sequence reads was done using the H3ABioNet 16S rDNA 
diversity analysis package (https://github.com/h3abionet/h3abionet16S) [21], with the 
exception that the taxonomy of representative reads was assigned using the SILVA 
version 132 database. The raw sequence files have been submitted to the European 
Nucleotide Archive (ENA) under the accession number PRJEB32077.  
 
Data analysis 
Statistical analyses were performed in STATA 14 (StataCorp LLC, Texas USA) and R 





were compared using Fisher’s exact test (for categorical parameters) and Kruskal-Wallis 
or Wilcoxon rank sum test (for continuous parameters). 
 
The richness of bacterial taxa within a single sample was represented by the number of 
operational taxonomic units (OTUs) and Chao1 index. Both richness and evenness 
(relative abundances of the different species) was characterized by Shannon's index.  
 
Interindividual differences, beta diversity, was determined using Bray-Curtis 
dissimilarity index [23] with sample depth set at 2000 reads. Beta diversity comparisons 
were explored using Principal Coordinate plots generated by the stats package in R 
Statistical software (http://www.r-project.org/). Comparisons were made using the 
Wilcoxon rank sum test where not specified otherwise. We also used Kruskal-Wallis test 
in cases where more than two groups were compared and the same groups were compared 
using the permutational multivariate analysis of variance (PERMANOVA) in QIIME2 
(version 2018.4) [24], with number of permutations set to 999. P-values were adjusted 
for multiple testing using the Benjamini-Hochberg method [25]. 
 
Relative abundance 
To assess relative abundance a linear discriminant analysis (LDA) was performed using 
LEfSe (linear discriminant analysis (LDA) effect size) [26] with default settings (alpha 
values for the statistical test 0.05). To reduce the number of markers, the effect size 
threshold was set to 1.0 for the plots. Relative abundance comparisons plots were 
generated using the MicrobiomeAnalyst web-based software tool with standard feature 
filtering [27]. Heatmaps were generated using only the taxa that were significantly 
different using the LEfSe comparison (Supplementary figure 1-3). The average fraction 
of each taxa was calculated from all samples within each group. The data was transformed 
to fractional abundance (Phyloseq) before performing the LEfSe analysis. All p-values 
reported are corrected for multiple testing using false discovery rate (FDR).  
 
Alpha diversity indices between study groups were compared using Wilcoxon rank-sum 
test and p-values were corrected for multiple testing using false discovery rate (FDR) 
procedure. Spearman´s rank correlation with Bonferroni correction was used to assess the 
association between alpha diversity indices and continuous parameters. We fitted linear 
regression model in order to estimate the association between HIV status, participant 
characteristics, presence of HIV-associated CLD and alpha diversity indices. Age and sex 




In total 149 HIV infected participants with CLD, 28 HIV infected participants without 
CLD, and 103 HIV uninfected participants were enrolled. The characteristics of study 
groups are presented in Table 1.  
 
HIV infected participants were older compared to the HIV uninfected participants ((15.6 
years (IQR 12.8-17.7) vs 9.9 (IQR 7.4-12.7), p<0.001)) and were more likely to be stunted 
and underweight compared to HIV uninfected participants (stunted: 41.2% vs 4.8%, 





experienced episodes of diarrhoea during the last three months prior to enrolment was 
also higher in the HIV infected than in HIV uninfected group (10.6% vs 2.9%, p=0.03). 
 
Alpha diversity  
Species richness estimates (OTUs, Chao1) were significantly higher in HIV uninfected 
compared to HIV infected participants. However, there was no difference in the Shannon 
index between these two study groups (Figure 1, Supplementary table 1). After 
adjustment for age and sex using linear regression analysis the negative association 
between richness indices and HIV status remained significant (p =0.03 for OTUs and 
p=0.002 for Chao1 index). The use of antibiotics during the three previous months did 
not change the significant effect of positive HIV status for the Chao1 index 
(Supplementary table 2). A sub-group analysis of virally suppressed/non-suppressed 
participants revealed no association between viral suppression and estimates of alpha 
diversity in our study population (Supplementary table 3). We stratified the HIV infected 
participants based on their time spent on ART (ART<5 years; n=53, ART 5-10 years; 
n=100, ART³10 years; n=23). When comparing HIV infected participants based on these 
subgroups, we found that participants who had been on ART ³ 10 years had an alpha 
diversity that was similar to the HIV uninfected study group (Table 2).  
 
There was no difference in alpha diversity indices between HIV infected participants with 
and without CLD (Supplementary table 4). The same was observed after adjusting for 
age and sex using regression analysis (Supplementary table 5). 
 
The association between participant characteristics and alpha diversity indices in HIV 
infected participants is presented in Supplementary table 5. Prolonged ART treatment 
was the only parameter significantly associated with a richer gut microbiota after 
adjustment for age and sex, suggesting a positive effect of prolonged ART. No parameters 




We found a significantly higher beta diversity amongst HIV infected participants, 
compared to HIV uninfected (p<0.01) (Figure 2a). Duration of ART had no impact on 
beta diversity when stratified by years spent on ART. There was no association between 
beta diversity and viral load suppression, type of ART regimen, time on ART and prior 
TB in HIV infected participants. 
 
HIV infected participants with CLD had higher beta diversity compared to both HIV 
uninfected (p<0.01) and HIV infected participants without CLD (p=0.03). There was no 
significant difference between HIV infected participants without CLD and HIV 
uninfected (p=0.74) (Figure 2b). Unweighted UniFrac analysis show similar results. 
 
Relative abundance of specific taxa 
We identified 26 different phyla in the rectal swabs from all participants, only five phyla 
contributed more than 1% of the total sequences of the entire dataset. Firmicutes (43.9%), 
Bacteroidetes (33.9%) and Epsilonbacteraeota (9%), previously within the phylum 
Proteobacteria), Actinobacteria (5.3%) and Proteobacteria (7.7%), accounted for 99.8 % 






HIV infected participants versus HIV uninfected participants  
At phylum level HIV infected participants had significantly lower abundance of 
Epsilonbacteraeota (7%) (p<0.01) and Bacteroidetes (32%) (p<0.01) compared to HIV 
uninfected participants (with 13% and 38% respectively) (Supplementary figure 4).  
 
At genus level HIV infected participants had enriched Corynebacterium (p<0.01), 
Lawsonella (p<0.01) and Collinsella (p=0.04) belonging to the Actinobacteria phylum; 
while in the Firmicutes phylum Finegoldia (p<0.01), Anaerococcus (p<0,01), 
Erysipelotrichaceae (p=0.02) and Lachnoclostridium (p=0.04) were enriched when 
compared to HIV uninfected. 
 
HIV uninfected participants, when compared to HIV infected, were enriched in 
Campylobacter (p < 0.01) belonging to the Epsilonbacteraeota phylum; Porphyromonas 
(p<0.01) and Prevotella (p=0.03) belonging to Bacteroidetes phylum; Eubacterium 
coprostanoligenes_group (p<0.01), Ruminococcaceae (p<0.01), Fastidiosipila (p<0.01), 
Fournierella (p<0.01), W5053 (p<0.01), Coprococcus (p=0.02) and Murdochiella 
(p<0.01) all belonging to the Firmicutes phylum (Figure 3).  
 
HIV infected participants with CLD had a higher abundance of the genus 
Faecalibacterium (p=0.05) belonging to the phylum Firmicutes, compared to participants 
without CLD. Participants without CLD had higher abundance of genus W5053 (p<0.01), 
phylum Firmicutes and Prevotella (p=0.05), phylum Bacteroidetes, compared to 
participants with CLD.  
 
Associations between characteristics of HIV infected participants and gut microbiota 
When we stratified HIV infected participants based on CD4 count (CD4£400 cells/mm 
vs >400 cells/mm), we found no statistically significant differences at the genus level. 
However, we found higher proportions at the family level of Enterobacteriaceae (p=0.02) 
and Burkholderiaceae (p=0.04) in those with CD4 counts £ 400 cells/mm, whereas 
Succinivibrionaceae (p=0.04) was higher in those with CD4 counts > 400 cells/mm. No 
differences in relative abundance were found at any taxonomic level between virally 
suppressed and non-suppressed participants (<1000 copies/ml vs ³1000 copies/ml).  
 
We compared the HIV infected participants based on ART duration sub groups to HIV 
uninfected using the LEfSe analysis. The longer the participants had been on ART, the 
fewer taxa was found to be significantly different between HIV infected and HIV 
uninfected (Supplementary figure 1-3), illustrated in heatmaps (Supplementary figure 5-
8). HIV infected participants who had been on ART³10 years are more similar to HIV 
uninfected than those on ART for less than 10 years. Genera such as Bacteroides, 
Prevotella, Porphyromonas, Blautia and Roseburia are similarly abundant in HIV 
uninfected and HIV infected participants who have been on ART³10 years. However, the 
genera Finegoldia and Corynebacterium remained significantly enriched in HIV infected 
participants on ART³10 years compared to HIV uninfected, whereas Ruminococcaceae 
remained significantly enriched in HIV uninfected compared to HIV infected participants 






We found no differences in relative abundance when comparing HIV infected participants 
on ART for <5 years to those on ART for 5-10 years or for ³10 years. 
 
Discussion 
Our study showed that gut microbiota in HIV infected ART-treated children was less 
diverse than in HIV uninfected children, however children who had been taking ART for 
10 years or more, had a more diverse microbiota resembling that of HIV uninfected 
children. Our results suggest that prolonged ART minimize the differences in gut 
microbiota between HIV infected and uninfected participants.  
 
Impact of HIV on gut microbiota 
A number of studies in adults demonstrated that HIV infection without treatment is 
associated with severe intestinal dysbiosis, reduced alpha diversity and increased beta 
diversity [9, 28, 29]. These changes may persist despite ART (5, 6, 10, 38, 39). Our results 
of overall lower alpha diversity and higher beta diversity in HIV infected ART-treated 
children support these findings.   
 
The published data are less consistent when it comes to relative abundance of specific 
taxa in HIV infected individuals. Types of specimens used, study populations, 
geographical area, sequencing method and false discovery may explain these conflicting 
results. For example, analysis of rectal swabs of HIV infected, ART treated participants 
in Nigeria found higher abundance of Finegoldia and Anaerococcus in the HIV infected 
population [30], which is consistent with our findings. However, in the same study 
Campylobacter was significantly enriched in HIV infected participants in contrast to our 
findings of enriched Campylobacter in the HIV uninfected group.   
 
Several studies showed enriched levels of Proteobacteria in HIV infected, ART naive 
individuals [6, 7, 9], with only one study showing similar findings in ART treated 
individuals [11]. We found an enrichment of Proteobacteria in HIV infected individuals, 
yet not statistically significant. However, we found a trend towards lower abundance of 
Proteobacteria with increasing time on ART.  
 
Impact of ART on gut microbiota 
At least two studies have found a negative impact of ART on gut microbiota diversity [9, 
30]. In a longitudinal study, Nowak P. et al. found significant decrease in the number of 
observed species and Shannon index after the introduction of ART. Our results does not 
contradict this, as they investigated the effect of ART initiation, with a relatively short 
follow up of 10 months [9]. In our population, we had no ART-naive participants, and 
minimum duration of ART was 1 year. We observed lower alpha diversity in those who 
were on ART for less than 10 years compared to HIV uninfected participants. 
 
Previous studies that have investigated the gut microbiome in individuals on long-term 
ART reported similar alpha diversity profiles in HIV infected, ART-treated individuals 
and HIV uninfected participants [11, 28]. For example, Dinh et al. found no significant 
difference in alpha diversity measures between HIV infected participants who were on 
suppressive ART for a median of 13.3 years and HIV uninfected controls [11]. This is 
similar to our findings for those participants who received ART for 10 or more years. The 





found that individuals with longer ART duration showed a closer resemblance to HIV 
uninfected individuals than to subjects with untreated chronic HIV infection [31]. These 
studies together with our findings support the ability of long-term ART to restore the 
HIV-associated dysbiotic gut microbiota. 
 
We did not observe an association between immunological or virological markers (VL 
and CD4 count) and gut microbiome diversity measures. In contrast, other studies showed 
significantly lower microbiome diversity in those with more severe HIV status [9, 32, 
33]. The findings of previous studies may have been affected by sample size and duration 
of ART. A longitudinal study with repeated measurements of VL, CD4 and microbiome 
profiles is needed to uncover the relationship between these parameters.  
 
We found enriched levels of Enterobacteriaceae in HIV infected participants with low 
CD4+ T-cell counts (£400 cells/mm3). Enterobacteriaceae may cause gastrointestinal and 
urinary tract infections in HIV infected children [33], however the clinical significance 
of this finding is unclear, as Enterobacteriaceae are found as part of the normal intestinal 
flora. Burkholderiaceae, also enriched in those with low CD4+ T-cell counts (£400 
cells/mm3), includes species known to cause severe lung infections in patients with cystic 
fibrosis [34].  
Gut-lung axis 
Recent evidence suggests that the gut microbiome is involved in maintaining lung health 
and an altered gut microbiome composition is often observed in patients with lung 
diseases [16, 17]. For example, low gut microbiome diversity during infancy has been 
linked to asthma at school age [35]. In our study, however, we did not observe any 
difference in alpha diversity estimates between participants with and without HIV-
associated CLD, though there were some significant differences in relative abundance of 
specific taxa. For example, the genus Faecalibacterium was enriched in HIV infected 
individuals with CLD while the genus Prevotella was enriched in HIV infected 
individuals without CLD. Interestingly, higher proportions of Prevotella have previously 
been shown in lung microbiota of children without asthma compared to asthmatic 
children and adults with chronic obstructive pulmonary disease (COPD) [36].  
 
Faecalibacterium have previously been regarded as a protective commensal, and is 
associated with a healthy gut. Depletion of this bacteria have been linked to the 
development of inflammatory bowel disease and asthma, and low levels have been shown 
in patients with cystic fibrosis [17, 37]. However, some studies have challenged this, by 
showing increased levels of the species Faecalibacterium prausnitzii in the gut 
microbiome of paediatric patients with untreated Crohn’s disease at the time of diagnosis 
[38]. Interestingly, a recent study also showed increased levels of Faecalibacterium in 
the gut microbiome of patients with active TB, suggesting that its role in disease is not 
entirely beneficial [39]. 
 
Co-trimoxazole prophylaxis  
Since the majority (90.8%) of HIV infected participants in our study received co-
trimoxazole prophylaxis, it is not possible to completely tease apart the effect of HIV 
from that of cotrimoxazole. Though it is known that antibiotics cause substantial changes 
in the gut microbiota, data regarding the impact of co-trimoxazole prophylaxis on gut 





impact of positive HIV status on richness estimates remained significant after accounting 
for co-trimoxazole prophylaxis. We also did not observe any effect of co-trimoxazole 
administration on alpha diversity in HIV infected participants. Our results are in line with 
several other studies where no significant difference in alpha diversity indices (OTUs, 
Shannon index) was observed in HIV infected individuals who took co-trimoxazole and 
those who did not [40-42]. 
 
Study strengths and limitations 
Our study is one of the first to assess the gut microbiome composition in children and 
adolescents with perinatally acquired HIV infection. Relatively large sample size and 
detailed characteristics of study participants allowed us to perform extensive statistical 
analysis. All participants in our study were from the same region - thus increasing the 
internal validity of our data.  
 
Our study was cross-sectional and is therefore unable to directly assess relationships over 
time. Further, we did not assess diet, social factors such as housing or level of education 
of the participants which may also have impact on gut microbiota. 
 
Conclusion 
To our knowledge, this study is the first to assess gut microbial composition of HIV 
infected children and adolescents in a setting with a very high HIV burden. Our results 
indicate that gut microbiota is altered in HIV infected children, though it improves with 
increasing duration of ART. Further studies, where the gut microbiota, markers of 
microbial translocation and immunological markers are measured are warranted to 
provide better insight to the pathogenesis of HIV and its related complications.  
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Figure 2. Beta-diversity comparison between study groups  
Primcipal cooridnate analysis-plot showing beta-diversity by Bray-Curtis dissimilarity 
comparing (a) HIV infected (red) and HIV uninfected (blue) participants (p<0.01) and (b) 
HIV infected with CLD (red), HIV infected without CLD (green) and HIV uninfected 
(blue) participants. P-value obtained using wilcoxon rank sum test.  
 










red = HIV infected, blue = HIV uninfected

















Figure 3. LEfSe plot (linear discriminant analysis (LDA) effect size) showing enriched 
taxa that are significantly different between HIV infected (blue) and HIV uninfected (red) 












































































































Supplementary files, tables and figures 
Supplementary table 1. Alpha diversity in HIV infected and HIV uninfected participants.  
 
 HIV infected group   
(N=177) 
HIV uninfected group 
(N=103) 
 
 Median, IQR p value* 
Observed OTUs  184 (142-226) 201 (168-240) 0.003 
Chao1  247.5 (197.8-296.8) 281.3 (237.2-328.4) <0.001 
Shannon index  4.1 (3.5-4.6) 4.0 (3.6-4.5) 0.83 
 
* p values were obtained using Wilcoxon rank-sum test and corrected for multiple testing using FDR 
  
 2 
Supplementary table 2. Association between HIV status and alpha diversity indices (linear regression analysis where alpha diversity 
index is the outcome and the HIV status is the dependent variable). 
 
 Univariate analysis Adjusted for BMI, age and sex Adjusted for BMI, age, sex, antibiotics 
in 3 previous months * 
 b coefficient (95% CI) p value b coefficient (95% CI) p value b coefficient (95% CI) p value 
Observed OTUs  -18.9 (-31.7 to -6.1) 0.004 -18.8 (-35.0 to -2.6) 0.02 -26.5 (-54.8 to 1.89) 0.07 
Chao1  -35.7 (-52.3 to -19.0) <0.001 -34.7 (-55.7 to -13.7) 0.001 -42.3 (-79.1 to -5.6) 0.02 
Shannon index  -0.1 (-0.2 to 0.1) 0.53 -0.1 (-0.3 to 0.1) 0.43 -0.3 (-0.7 to 0.1) 0.16 
 
* interaction term between HIV status and antibiotics in the three previous months status was introduced into the adjusted model. 
  
 3 
Supplementary table 3.  Alpha diversity in HIV infected-suppressed, HIV infected non-suppressed and HIV uninfected participants.  
 













HIV+, suppressed vs 
HIV+, non-suppressed 
 
 Median, IQR p value 
Observed OTUs  192.5 (145.5-228.5) 176 (138-220) 201 (168-240) 0.05* 0.005* 0.06** 
Chao1  259.3 (201.2-302.1) 233.2 (175-276)  281.3 (237.2-328.4) 0.006* <0.001* 0.02** 
Shannon index  4.10 (3.48-4.61) 4.06 (3.60-4.57) 4.0 (3.6-4.5) 0.51* 0.37* 0.47** 
 
* presented p values were obtained from regression model adjusted for BMI, age and sex where HIV status was introduced as an independent variable and alpha diversity 
estimates as a dependent (outcome) variable.  




Supplementary table 4. HIV infected participants with and without chronic lung disease. 
 
 HIV infected with chronic lung 
disease (N=149) 
HIV infected without chronic 
lung disease (N=28) 
 
 Median, IQR p value* 
Observed OTUs  183 (144-228) 191 (140-216) 0.64 
Chao1  245.9 (199.3-297.6) 248.7 (191.9-276.8) 0.68 
Shannon index  4.1 (3.5-4.6) 4.0 (3.5-4.7) 0.80 
 
* p values were obtained using Wilcoxon rank-sum test and corrected for multiple testing using FDR 
 
 5 
Supplementary table 5. Association between characteristics of HIV infected participants (independent variables) and alpha diversity 
indices (dependent variables) in linear regression analysis adjusted for age and sex.  
 
 Richness Richness + evenness 
Covariates  OTUs Chao1 Shannon 
 b coefficients (95% CI) p value b coefficients (95% CI) p value b coefficients (95% CI) p value 
Age, years -1.94 (-4.33 to 0.46) 0.11 -2.63 (-5.66 to 0.40) 0.09 -0.007 (-0.04 to 0.03) 0.68 
Sex (ref. male) 1.07 (-15.0 to 17.1) 0.90 10.4 (-9.92 to 30.7) 0.31 -0.02 (-0.26 to 0.22) 0.85 
Stunted (ref. no) -4.23 (-20.6 to 12.1) 0.61 -9.01 (-29.7 to 11.7) 0.39 0.05 (-0.19 to 0.30) 0.67 
Underweight (ref. no) -0.35 (-16.5 to 15.8) 0.97 -10.3 (-30.8 to 10.1) 0.32 0.12 (-0.12 to 0.36) 0.33 
Viral load, log copies/ml -2.91 (-9.01 to 3.19) 0.35 -6.05 (-13.7 to 1.62) 0.12 0.04 (-0.05 to 0.14) 0.34 
VL, categories       
Suppressed ref.  ref.  ref.  
VL (³1000 copies/ml) -10.3 (-27.1 to 6.44) 0.23 -19.4 (-40.5 to 1.73) 0.07 -0.01 (-0.27 to 0.24) 0.90 
CD4£400 cells/mm3 (ref>400 
cells/mm3) 
-5.16 (-23.9 to 13.6) 0.59 -12.1 (-35.8 to 11.5) 0.31 0.15 (-0.13 to 0.43) 0.29 
 6 
Years on ART  2.98 (0.14 to 5.81) 0.04 4.00 (0.43 to 7.58) 0.03 0.01 (-0.03 to 0.06) 0.49 
Years on ART, categories        
<5years ref.  ref.  ref.  
5-10 years  14.5 (-3.57 to 32.7) 0.11 22.2 (-0.67 to 45.1) 0.06 0.09 (-0.18 to 0.36) 0.52 
³10 years 34.5 (7.37 to 61.6) 0.01 39.9 (5.58 to 74.2) 0.02 0.36 (-0.05 to 0.77) 0.08 
Co-trimoxazole prophylaxis (ref.no) 4.24 (-22.1 to 30.6) 0.75 2.92 (-30.3 to 36.2) 0.86 0.19 (-0.21 to 0.58) 0.35 
FEV1 z-score -0.38 (-6.15 to 5.38) 0.89 -0.95 (-8.26 to 6.35) 0.80 -0.04 (-0.13 to 0.04) 0.30 
Diagnosis of chronic lung diaseade 
(ref.no) 
4.71 (-17.4 to 26.8) 0.67 6.00 (-22.0 to 34.0) 0.67 0.05 (-0.28 to 0.37) 0.78 
ART regimen (ref. NNRTI) 0.25 (-17.0 to 17.5) 0.98 -5.34 (-27.1 to 16.4) 0.63 0.03 (-0.23 to 0.28) 0.84 
Previously treated for TB (ref.no) -3.09 (-20.5 to 14.3) 0.73 -3.42 (-25.4 to 18.5) 0.76 0.09 (-0.17 to 0.35) 0.48 




Supplementary table 6. Association between characteristics of HIV uninfected participants (independent variables) and alpha diversity 
indices (dependent variables) in linear regression analysis adjusted for age and sex. 
 
 Richness  Richness + evenness 
Covariates  OTUs Chao1 Shannon 
 b coefficients (95% CI) p value b coefficients (95% CI) p value b coefficients (95% CI) p value 
Age, years 3.14 (-0.14 to 6.43) 0.06 4.24 (-0.23 to 8.70) 0.06 0.02 (-0.02 to 0.07) 0.27 
Sex (ref. male) -1.11(-20.9 to 18.6) 0.91 5.63 (-21.2 to 32.4) 0.68 0.24 (-0.03 to 0.52) 0.08 
Stunted (ref. no) -18.6 (-63.9 to 26.8) 0.42 -40.8 (-102.1 to 20.5) 0.19 -0.13 (-0.76 to 0.51) 0.69 
Underweight (ref. no) -15.4 (-60.8 to 30.0) 0.50 -38.1 (-99.5 to 23.3) 0.22 0.10 (-0.53 to 0.74) 0.74 
FEV1 z-score 4.10 (-9.39 to 17.6) 0.55 3.94 (-14.7 to 22.5) 0.67 0.07 (-0.11 to 0.25) 0.43 
Episodes of diarrhea 
(ref.no) 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































                      APPENDIX I 
 
BO.03a BREATHE Trial   
Bronchopulmonary response to azithromycin treatment for chronic lung disease in HIV-infected children 
BASELINE CLINICAL FORM - MAIN STUDY 
V2.1 Baseline clinical Form Main study 30 January 2017                                                                                 Page 1 of 5 
F01 STUDN 
Study number       
F02 DATE 




HIV clinic number              
F05 STATUS Is the participant aware of his/her HIV status? Yes   No   
F06 DATEHIV 
Date of HIV diagnosis (if 
day unknown assign 15, if 
month unknown assign JUN) 
  /   /20    
Unknown    
F07 AGEHIV 
Age at HIV diagnosis 




Was HIV diagnosis done 
because: (check ONE box only) 
 







Date of ART initiation (if 
day unknown assign 15, if 




Age at ART initiation  
(Years completed, 0 if under 
one year) 
   
F11 COTRI Is the participant taking cotrimoxazole? Yes   No  Don’t Know  
  
BO.03a BREATHE Trial   
Bronchopulmonary response to azithromycin treatment for chronic lung disease in HIV-infected children 
BASELINE CLINICAL FORM - MAIN STUDY 
V2.1 Baseline clinical Form Main study 30 January 2017                                                                                 Page 2 of 5 
F13 DRUGS 
Please tick current ART drugs the child is taking: (tick all that apply) 
AZT (zidovudine) Yes   No  
D4T (stavudine) Yes   No  
TNF (tenofovir) Yes   No  
ABC(Abacavir) Yes   No  
3TC (lamuvidine) Yes   No  
DDI (didanosine) Yes   No  
NVP(Nevirapine) Yes   No  
EFV(Efavirenz) Yes   No  
ATV (atazanavir)/R (ritonavir) Yes   No  
LPV (kaletra, alluvia)/R(ritonavir) Yes   No  
Other ART Drug Yes   No  
 
 
Specify Other ART Drug ………………………………………………………………….. 
CLINICAL HISTORY 
F14 ADM 
Has the participant been admitted to 
hospital for chest problems in the last 12 
months? 
Yes   No  Don’t Know  
F15 NADM 
If yes, how many times has the participant 
been admitted to hospital for chest 
problems in the last 12 months   
     NA   
F16 TBTREAT Has the participant ever been treated for TB? Yes   No  Don’t Know  
F17 NOTBTREAT 
If yes, how many times has the participant 
been treated for TB?     NA   
F18 BREATH Is the participant currently breathless? Yes   No  
F19 MRC5 
Does the participant get breathless when 
dressing or too breathless to leave the 
house? 
 Yes   No  
F20 MRC4 Does the participant have to stop for breath after walking 100 m? Yes   No  
F21 MRC3 
Does the participant walk slower than 
most people or has to stop after 15 
minutes walking? 
Yes   No  
BO.03a BREATHE Trial   
Bronchopulmonary response to azithromycin treatment for chronic lung disease in HIV-infected children 
BASELINE CLINICAL FORM - MAIN STUDY 
V2.1 Baseline clinical Form Main study 30 January 2017                                                                                 Page 3 of 5 
F22 MRC2 Is the participant short of breath when hurrying on the level or walking uphill? Yes   No  
F23 MRC1 Does the participant get breathless on moderate exercise? Yes   No  
F24 MRCSCORE 
What is the MRC Dyspnoea Scale score? 
(please check consistency with answers on 
questions F18 to F23) 
 
  
F25 COUGH Does the participant have a cough now? Yes   No  
F26 COUGHT 





Getting worse   
Do not know   
Not coughing   
F27 SPUTUM Does the participant cough up sputum? Yes   No  N/A    
F28 SPUTUMQ 
How much sputum does the participant 
cough up each day? (tick what applies) 
 
No Sputum   
Less than a table spoon   
A few table spoons    
A cup     
Do not know     
Not coughing    
 
F29 LYWH Does the participant get wheezing or whistling in the chest? Yes   No  Don’t Know  
F30 INH Does the participant use an inhaler? Yes   No  Don’t Know  
F31 FINH 
How often does the participant use an 
inhaler? (tick what applies) 
 
Once a week   
Daily    
More than once a week    
Don´t know      
Not applicable   
BO.03a BREATHE Trial   
Bronchopulmonary response to azithromycin treatment for chronic lung disease in HIV-infected children 
BASELINE CLINICAL FORM - MAIN STUDY 
V2.1 Baseline clinical Form Main study 30 January 2017                                                                                 Page 4 of 5 
F32 SALBT Does the participant use salbutamol tablets? Yes   No  Don’t Know  
F33 ASTHMA 
Has the participant ever been 
told by a doctor or nurse that 
he or she has asthma? 
Yes   No  Don’t Know  
EXAMINATION 
F34 WEIGHT Weight   .  Kg 
F35 HEIGHT Height    .  cm 
F36 RR Respiratory rate    breaths per minute 
F37 HR Heart rate     per minute 
F38 SAT Oxygen saturation     % 
ELIGIBILITY FOR SHUTTLE WALK TEST 
F41 SHUTY  Is the participant capable of doing the shuttle walk test Yes   No  
F42 SHUTN 
If not capable of doing a shuttle 
walk test, give reason why not 
(check all reasons that apply): 
SpO2 <88%   
RR>30/min  
Resting heart rate >120/min  
Feels too ill to exercise   
Unable to stand/ walk  
 Other   
If other, specify _______________ 
___________________________________ 
FOR THOSE ELIGIBLE FOR SHUTTLE WALK TEST 
F43 SHUTM Time participant walked   minutes    seconds 
F44 SHUTO2N O2 saturation immediately after SWT    % 
F45 SHUTHRN Heart rate immediately after SWT     /min 
F46 SHUTRRN Respiratory rate immediately after SWT   /min 
F48 SHUTHR1 Heart rate 1 minute after SWT     /min 




BO.03a BREATHE Trial   
Bronchopulmonary response to azithromycin treatment for chronic lung disease in HIV-infected children 
BASELINE CLINICAL FORM - MAIN STUDY 
V2.1 Baseline clinical Form Main study 30 January 2017                                                                                 Page 5 of 5 
Staggering   
Excessive sweating (diaphoresis)   
Did not reach next point(beep)   
 Other   
If other, Specify ________________________ 
FORMS AND TESTS  
F51 TESTS 
Which tests were 
collected? (tick all that 
applies) 
Blood sample immunology Yes   No  N/A  (BO.25) 
Sputum storage Yes   No  N/A  (BO.26) 
NPA Yes   No  N/A   (BO.28) 
Rectal Swab storage Yes   No  N/A   (BO.29) 
Stool  storage Yes   No  N/A   (BO.27) 
Viral Load Yes   No  N/A   (BO.19) 
CD4 Yes   No  N/A   (BO.18) 
Cardiac Echo Yes   No  N/A   (BO.14)  
F52 LOGD Drug recording diary given to designated caregiver? Yes   No  
F53 PHARM Has the pharmacy form been completed (BO.13)? Yes   No  




Cardiac echo appointment date 


















                      APPENDIX II 
 
BO.03b BREATHE Trial   
Bronchopulmonary response to azithromycin treatment for chronic lung disease in HIV-infected children 
BASELINE CLINICAL FORM COMPARISON GROUP 
 
 
V2.1 Baseline clinical Form comparison group 30 January 2017                                                                     Page 1 of 2 
 
G01 STUDN 
Study number       
G02 DATE 




HIV clinic number              
G05 STATUS Is the participant aware of his/her HIV status? Yes   No   
G06 DATEHIV 
Date of HIV diagnosis (if day 
unknown assign 15, if month 
unknown assign JUN)) 
  /   /20   Unknown    
G07 AGEHIV 
Age at HIV diagnosis 
(Years completed, 0 if under one year)    years 
G08 REASONHIV 
Was diagnosis done because: 
(check ONE box only) 
 







Date of ART initiation (if day 
unknown assign 15, if month 




Age at ART initiation (Years 
completed, 0 if under one year)    
G11 COTRI Is the participant taking cotrimoxazole? Yes   No  Don’t Know  
  
BO.03b BREATHE Trial   
Bronchopulmonary response to azithromycin treatment for chronic lung disease in HIV-infected children 
BASELINE CLINICAL FORM COMPARISON GROUP 
 
 
V2.1 Baseline clinical Form comparison group 30 January 2017                                                                     Page 2 of 2 
 
G13 DRUGS 
Please tick current ART drugs the child is taking: (tick all that apply) 
AZT (zidovudine) Yes   No  
D4T (stavudine) Yes   No  
TNF (tenofovir) Yes   No  
ABC(Abacavir) Yes   No  
3TC (lamuvidine) Yes   No  
DDI (didanosine) Yes   No  
NVP(Nevirapine) Yes   No  
EFV(Efavirenz) Yes   No  
ATV (atazanavir)/R (ritonavir) Yes   No  
LPV (kaletra, alluvia)/R(ritonavir) Yes   No  
Other ART Drug Yes   No  
 
Specify Other ART Drug ………………………………………………………………….. 
CLINICAL HISTORY 
G14 ADM Has the participant been admitted to hospital for chest problems in the last 12 months? Yes   No  Don’t Know  
G15 NADM 
If yes, how many times has the participant been 
admitted to hospital for chest problems in the 
last 12 months   
    NA   
G16 TBTREAT Has the participant ever been treated for TB? Yes   No  Don’t Know  
G17 NOTBTREAT 
If yes, how many times has the participant been 
treated for TB?          NA   
LABORATORY EVALUATIONS 
G18 TESTS 
Which tests were 
collected? (tick all that 
applies)?  
CD4 Yes   No  N/A   (BO.18) 
Viral Load Yes   No  N/A   (BO.18 
Blood sample immunology Yes   No  N/A   (BO.25) 
Sputum storage Yes   No  N/A   (BO.26) 
NPA Yes   No  N/A   (BO.28) 
Rectal Swab storage Yes   No  N/A   (BO.29) 
Stool  storage Yes   No  N/A   (BO.27) 
G19 FORM FORM B04 (SCHOOLING CRF) Completed 
Yes   No  













                      APPENDIX III 
 
BO.15 BREATHE Trial   
Bronchopulmonary response to azithromycin treatment for chronic lung disease in HIV-infected 
children 
Exhaled Nitric Oxide FORM 
 Version 2.1: 30 January 2017        Page 1 of 3 
 
Measurement of fractional exhaled nitric oxide in children and adolescents 
N00 STUDTYPE What kind of study is it? 
Breathe Main  
Breathe Control  
N01 STUDN Study number 
       
N02 DATE Date of interview and  eNO test (dd/mm/yyyy) 
   /  /     
N03 TIME Time of eNO test 
 
N04 VISIT Type of visit 
Enrol 12months  
N04b MEASURE Acceptable measurement done 
(If Yes Complete the rest of the questionnaire, If No Stop  
here, end of test)) 
YES NO  
Fractional exhaled nitric oxide (eNO) measurement  
N35 TIMEXHALE The exhalation time of the measurement 10 s , 6 s  
N35 NO1 First measurement ppb (5-300)    
N36 NO2 Second measurement ppb (5-300)    
N37 DIFF Percent difference between two measurements ≤10%  
YES NO  
N38 NO3 If >10%, the third measurement ppb (5-300)    
COM  Any Comment (Patient could not do second test 
 
N05 BRTH Does the participant currently have any 
breathing problems? YES NO  
N06 PAIN Does the participant have any pain or physical 
problem that may prevent him/her from taking 
a deep breath and exhaling forcefully? 
YES NO  
N07 SMKH Within the last hour, has the participant 
smoked a cigarette, cigar,pipe or used any 
other tobacco product? 
YES NO  
N08 EXCH Within the last hour, has the participant  
exercised strenuously? YES NO  
N09 DRKH Within the last hour, has the participant had 
anything to eat or drink ? YES NO  
N10 VEGH Within the last 3 hours has the participant 
eaten any vegetables? YES NO  
N11 VGN If (N10) YES, please name: 
(e.g:  beets, covo/rape, broccolo, cabbage, celery, 




BO.15 BREATHE Trial   
Bronchopulmonary response to azithromycin treatment for chronic lung disease in HIV-infected 
children 
Exhaled Nitric Oxide FORM 
 Version 2.1: 30 January 2017        Page 2 of 3 
 
N12 MEATH Within the last three hours, has the participant eaten 
any meat? YES NO  
N13 MEATN If (N12) YES, please name  




N14 CORTD Within the last two days, has the participant used any 
oral or inhaled corticosteroids or β2 agonists? YES NO  
N15 RESPD Within the last 7 days, has the participant had a cough, 
cold, phlegm, runny nose or other respiratory illness? Do 
not count allergies or hay fever. 
YES NO  
CLINICAL HISTORY 
N16 SMKE Does the participant smoke? 
YES NO quit smoking  
N17 SMKF Are the members of participant's family/people the 
participant living with smoking? YES NO Don't know  
N18 MEDS Does the participant take any medications/drugs 
besides ART? YES NO Don't know  
N19 MEDSN If yes, please name what medications/drugs.   
-------------------------------------- 
N20 SULB Does the participant use salbutamol tablets/inhaler? 
YES NO Don't know  
N21 CORTE Has the participant ever taken corticosteroids, long-











If the answer (N21) YES, please name (select all that apply): 
corticosteroids (budesonide/fluticasone) -brown/orange inhaler  
long-term b2 agonists (formoterol/salmeterol)-purple inhaler  
LRA (montelukast (egsingulair)   
methylxanthines(theophylline)   
N23 ASTH Has the participant ever had asthma? 
YES NO Don't know  
N24 WHZ Has the participant everexperienced wheezing, 
nocturnal tightness in the chest, attacks of shortness of 
breath following strenuous activity, at rest or at night 
time? 
YES NO Don't know  
N25 HAY Has the participant ever had hay fever? 
YES NO Don't know  
BO.15 BREATHE Trial   
Bronchopulmonary response to azithromycin treatment for chronic lung disease in HIV-infected 
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Exhaled Nitric Oxide FORM 
 Version 2.1: 30 January 2017        Page 3 of 3 
 
N26 SNZ Has the participant) ever had a problem with sneezing, 
or a runny, or a blocked nose, or nasal itching when the 
participant DID NOT have a cold or the flu? 
YES NO Don't know  
N27 WATE If (N26) YES, has this nose problems been accompanied 
by itchy-watery eyes? YES NO Don't know  
N28 CONJ Has the participant ever had allergic conjunctivitis? 
YES NO Don't know  
N29 DERM Has the participant ever had atopic dermatitis 
(eczema)? YES NO Don't know  
N30 RASH Has the participant ever had a rash which was coming 
and going? YES NO Don't know  
N31 ITCH If (N30) YES, had this caused itching or scratching? 
YES NO Don't know  
N32 ALLGF Does the participant have any known food allergies? 
YES NO Don't know  
N33 ALLEGN If (N32) YES,  please name: 
(e.g: cow's milk, egg whites, poultry, seafood, nuts) 
 
-------------------------------------- 
N34 REACTF Has the participant ever experienced bloating, itchy skin 
rash, tingling in the tongue/lips/throat, swelling or 
wheezing after eating some types of food? Do not count 
food poisoning. 
YES NO Don't know  
 
 
